1
|
Brollo M, Salvator H, Grassin-Delyle S, Glorion M, Descamps D, Buenestado A, Naline E, Tenor H, Tiotiu A, Devillier P. The IL-4/13-induced production of M2 chemokines by human lung macrophages is enhanced by adenosine and PGE 2. Int Immunopharmacol 2024; 128:111557. [PMID: 38266451 DOI: 10.1016/j.intimp.2024.111557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Revised: 01/12/2024] [Accepted: 01/15/2024] [Indexed: 01/26/2024]
Abstract
BACKGROUND AND PURPOSE Lung macrophages (LMs) are critically involved in respiratory diseases. The primary objective of the present study was to determine whether or not an adenosine analog (NECA) and prostaglandin E2 (PGE2) affected the interleukin (IL)-4- and IL-13-induced release of M2a chemokines (CCL13, CCL17, CCL18, and CCL22) by human LMs. EXPERIMENTAL APPROACH Primary macrophages isolated from resected human lungs were incubated with NECA, PGE2, roflumilast, or vehicle and stimulated with IL-4 or IL-13 for 24 h. The levels of chemokines and PGE2 in the culture supernatants were measured using ELISAs and enzyme immunoassays. KEY RESULTS Exposure to IL-4 (10 ng/mL) and IL-13 (50 ng/mL) was associated with greater M2a chemokine production but not PGE2 production. PGE2 (10 ng/mL) and NECA (10-6 M) induced the production of M2a chemokines to a lesser extent but significantly enhanced the IL-4/IL-13-induced production of these chemokines. At either a clinically relevant concentration (10-9 M) or at a concentration (10-7 M) that fully inhibited phosphodiesterase 4 (PDE4) activity, roflumilast did not increase the production of M2a chemokines and did not modulate their IL-13-induced production, regardless of the presence or absence of PGE2. CONCLUSIONS NECA and PGE2 enhanced the IL-4/IL-13-induced production of M2a chemokines. The inhibition of PDE4 by roflumilast did not alter the production of these chemokines. These results contrast totally with the previously reported inhibitory effects of NECA, PGE2, and PDE4 inhibitors on the lipopolysaccharide-induced release of tumor necrosis factor alpha and M1 chemokines in human LMs.
Collapse
Affiliation(s)
- Marion Brollo
- Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France
| | - Hélène Salvator
- Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France
| | - Stanislas Grassin-Delyle
- Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France; Department of Airway Diseases, Thoracic surgery, Foch Hospital, Suresnes, France
| | - Mathieu Glorion
- Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; INSERM U1173, Infection & Inflammation, Département de Biotechnologie de la Santé, Université Paris-Saclay, Montigny-le-Bretonneux, France
| | - Delphyne Descamps
- VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, Jouy-en-Josas, France
| | - Amparo Buenestado
- Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France
| | - Emmanuel Naline
- Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France
| | | | - Angelica Tiotiu
- Department of Pulmonary Medicine, University Hospital Saint-Luc, Institut of Experimental and Clinical Research (IREC), University of Louvain, Brussels, Belgium
| | - Philippe Devillier
- Laboratory of Research in Respiratory Pharmacology, Faculté des Sciences de la Vie Simone Veil, VIM, UMR-0892, INRAE, UVSQ, Université Paris-Saclay, France; Department of Airway Diseases, Respiratory Pharmacology Unit, Foch Hospital, Suresnes, France.
| |
Collapse
|
2
|
Gouin C, Vu Manh TP, Jouneau L, Bevilacqua C, De Wolf J, Glorion M, Hannouche L, Urien C, Estephan J, Roux A, Magnan A, Le Guen M, Da Costa B, Chevalier C, Descamps D, Schwartz-Cornil I, Dalod M, Sage E. Cell type- and time-dependent biological responses in ex vivo perfused lung grafts. Front Immunol 2023; 14:1142228. [PMID: 37465668 PMCID: PMC10351384 DOI: 10.3389/fimmu.2023.1142228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 06/13/2023] [Indexed: 07/20/2023] Open
Abstract
In response to the increasing demand for lung transplantation, ex vivo lung perfusion (EVLP) has extended the number of suitable donor lungs by rehabilitating marginal organs. However despite an expanding use in clinical practice, the responses of the different lung cell types to EVLP are not known. In order to advance our mechanistic understanding and establish a refine tool for improvement of EVLP, we conducted a pioneer study involving single cell RNA-seq on human lungs declined for transplantation. Functional enrichment analyses were performed upon integration of data sets generated at 4 h (clinical duration) and 10 h (prolonged duration) from two human lungs processed to EVLP. Pathways related to inflammation were predicted activated in epithelial and blood endothelial cells, in monocyte-derived macrophages and temporally at 4 h in alveolar macrophages. Pathways related to cytoskeleton signaling/organization were predicted reduced in most cell types mainly at 10 h. We identified a division of labor between cell types for the selected expression of cytokine and chemokine genes that varied according to time. Immune cells including CD4+ and CD8+ T cells, NK cells, mast cells and conventional dendritic cells displayed gene expression patterns indicating blunted activation, already at 4 h in several instances and further more at 10 h. Therefore despite inducing inflammatory responses, EVLP appears to dampen the activation of major lung immune cell types, what may be beneficial to the outcome of transplantation. Our results also support that therapeutics approaches aiming at reducing inflammation upon EVLP should target both the alveolar and vascular compartments.
Collapse
Affiliation(s)
- Carla Gouin
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Thien-Phong Vu Manh
- Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France
| | - Luc Jouneau
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Université Paris-Saclay, INRAE, UVSQ, BREED, 78350, Jouy-en-Josas, France
| | - Claudia Bevilacqua
- Université Paris-Saclay, INRAE, AgroParisTech, GABI, 78350, Jouy-en-Josas, France
| | - Julien De Wolf
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France
| | - Matthieu Glorion
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France
| | - Laurent Hannouche
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France
| | - Céline Urien
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Jérôme Estephan
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Antoine Roux
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Department of Pulmonology, Foch Hospital, Suresnes, France
| | - Antoine Magnan
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Department of Pulmonology, Foch Hospital, Suresnes, France
| | - Morgan Le Guen
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Department of Anesthesiology, Foch Hospital, Suresnes, France
| | - Bruno Da Costa
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | | | - Delphyne Descamps
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | | | - Marc Dalod
- Aix-Marseille University, CNRS, INSERM, CIML, Centre d'Immunologie de Marseille-Luminy, Turing Center for Living Systems, Marseille, France
| | - Edouard Sage
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
- Department of Thoracic Surgery and Lung Transplantation, Foch Hospital, Suresnes, France
| |
Collapse
|
3
|
Fix J, Descamps D, Galloux M, Ferret C, Bouguyon E, Zohari S, Näslund K, Hägglund S, Altmeyer R, Valarcher JF, Riffault S, Eléouët JF. Screening antivirals with a mCherry-expressing recombinant bovine respiratory syncytial virus: a proof of concept using cyclopamine. Vet Res 2023; 54:36. [PMID: 37069656 PMCID: PMC10111787 DOI: 10.1186/s13567-023-01165-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Accepted: 03/17/2023] [Indexed: 04/19/2023] Open
Abstract
Bovine respiratory syncytial virus (BRSV) is a pathogenic pneumovirus and a major cause of acute respiratory infections in calves. Although different vaccines are available against BRSV, their efficiency remains limited, and no efficient and large-scale treatment exists. Here, we developed a new reverse genetics system for BRSV expressing the red fluorescent protein mCherry, based on a field strain isolated from a sick calf in Sweden. Although this recombinant fluorescent virus replicated slightly less efficiently compared to the wild type virus, both viruses were shown to be sensitive to the natural steroidal alkaloid cyclopamine, which was previously shown to inhibit human RSV replication. Our data thus point to the potential of this recombinant fluorescent BRSV as a powerful tool in preclinical drug discovery to enable high throughput compound screening.
Collapse
Affiliation(s)
- Jenna Fix
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Delphyne Descamps
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Marie Galloux
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Cécile Ferret
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Edwige Bouguyon
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | - Siamak Zohari
- Department of Microbiology, National Veterinary Institute (SVA), Uppsala, Sweden
| | - Katarina Näslund
- Department of Microbiology, National Veterinary Institute (SVA), Uppsala, Sweden
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Sara Hägglund
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | | | - Jean-François Valarcher
- Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - Sabine Riffault
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350, Jouy-en-Josas, France
| | | |
Collapse
|
4
|
Mathieu E, Marquant Q, Chain F, Bouguyon E, Saint-Criq V, Le-Goffic R, Descamps D, Langella P, Tompkins TA, Binda S, Thomas M. An Isolate of Streptococcus mitis Displayed In Vitro Antimicrobial Activity and Deleterious Effect in a Preclinical Model of Lung Infection. Nutrients 2023; 15:nu15020263. [PMID: 36678133 PMCID: PMC9867278 DOI: 10.3390/nu15020263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 12/19/2022] [Accepted: 12/23/2022] [Indexed: 01/06/2023] Open
Abstract
Microbiota studies have dramatically increased over these last two decades, and the repertoire of microorganisms with potential health benefits has been considerably enlarged. The development of next generation probiotics from new bacterial candidates is a long-term strategy that may be more efficient and rapid with discriminative in vitro tests. Streptococcus strains have received attention regarding their antimicrobial potential against pathogens of the upper and, more recently, the lower respiratory tracts. Pathogenic bacterial strains, such as non-typable Haemophilus influenzae (NTHi), Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus), are commonly associated with acute and chronic respiratory diseases, and it could be interesting to fight against pathogens with probiotics. In this study, we show that a Streptococcus mitis (S. mitis) EM-371 strain, isolated from the buccal cavity of a human newborn and previously selected for promising anti-inflammatory effects, displayed in vitro antimicrobial activity against NTHi, P. aeruginosa or S. aureus. However, the anti-pathogenic in vitro activity was not sufficient to predict an efficient protective effect in a preclinical model. Two weeks of treatment with S. mitis EM-371 did not protect against, and even exacerbated, NTHi lung infection.
Collapse
Affiliation(s)
- Elliot Mathieu
- Micalis Institute, Institut National de Recherche pour L’Agriculture, L’Alimentation et L’Environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350 Jouy-en-Josas, France
- Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571 Paris, France
- Correspondence:
| | - Quentin Marquant
- Université Paris-Saclay, INRAE, UVSQ, VIM, F-78350 Jouy-en-Josas, France
- Laboratoire VIM-Suresnes, Hôpital Foch, F-92150 Suresnes, France
| | - Florian Chain
- Micalis Institute, Institut National de Recherche pour L’Agriculture, L’Alimentation et L’Environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350 Jouy-en-Josas, France
- Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571 Paris, France
| | - Edwige Bouguyon
- Université Paris-Saclay, INRAE, UVSQ, VIM, F-78350 Jouy-en-Josas, France
| | - Vinciane Saint-Criq
- Micalis Institute, Institut National de Recherche pour L’Agriculture, L’Alimentation et L’Environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350 Jouy-en-Josas, France
- Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571 Paris, France
| | - Ronan Le-Goffic
- Université Paris-Saclay, INRAE, UVSQ, VIM, F-78350 Jouy-en-Josas, France
| | - Delphyne Descamps
- Université Paris-Saclay, INRAE, UVSQ, VIM, F-78350 Jouy-en-Josas, France
| | - Philippe Langella
- Micalis Institute, Institut National de Recherche pour L’Agriculture, L’Alimentation et L’Environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350 Jouy-en-Josas, France
- Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571 Paris, France
| | | | - Sylvie Binda
- Lallemand Health Solutions, Montreal, QC H4P 2R2, Canada
| | - Muriel Thomas
- Micalis Institute, Institut National de Recherche pour L’Agriculture, L’Alimentation et L’Environnement (INRAE), AgroParisTech, Université Paris-Saclay, UMR1319, F-78350 Jouy-en-Josas, France
- Paris Center for Microbiome Medicine (PaCeMM) FHU, AP-HP, F-75571 Paris, France
| |
Collapse
|
5
|
Mayer N, Beaulieu S, Jiménez-Galán Á, Patchkovskii S, Kornilov O, Descamps D, Petit S, Smirnova O, Mairesse Y, Ivanov MY. Role of Spin-Orbit Coupling in High-Order Harmonic Generation Revealed by Supercycle Rydberg Trajectories. Phys Rev Lett 2022; 129:173202. [PMID: 36332250 DOI: 10.1103/physrevlett.129.173202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 07/26/2022] [Accepted: 09/08/2022] [Indexed: 06/16/2023]
Abstract
High-harmonic generation is typically thought of as a sub-laser-cycle process, with the electron's excursion in the continuum lasting a fraction of the optical cycle. However, it was recently suggested that long-lived Rydberg states can play a particularly important role in high harmonic generation by atoms driven by the combination of the counterrotating circularly polarized fundamental light field and its second harmonic. Here we report direct experimental evidence of very long and stable Rydberg trajectories contributing to high-harmonic generation in such fields. We track their dynamics inside the laser pulse using the spin-orbit evolution in the ionic core, utilizing the spin-orbit Larmor clock. We confirm their effect on harmonic emission both via microscopic simulations and by showing how this radiation can lead to a well-collimated macroscopic far-field signal. Our observations contrast sharply with the general view that long-lived Rydberg orbits should generate negligible contribution to the macroscopic far-field high harmonic response of the medium.
Collapse
Affiliation(s)
- N Mayer
- Max-Born-Institute, Max-Born Straße 2A, 12489 Berlin, Germany
| | - S Beaulieu
- Université de Bordeaux-CNRS-CEA, Centre Lasers Intenses et Applications (CELIA), UMR5107, F33405 Talence, France
| | - Á Jiménez-Galán
- Max-Born-Institute, Max-Born Straße 2A, 12489 Berlin, Germany
- Joint Attosecond Science Laboratory, National Research Council of Canada and University of Ottawa, Ottawa, Canada
| | - S Patchkovskii
- Max-Born-Institute, Max-Born Straße 2A, 12489 Berlin, Germany
| | - O Kornilov
- Max-Born-Institute, Max-Born Straße 2A, 12489 Berlin, Germany
| | - D Descamps
- Université de Bordeaux-CNRS-CEA, Centre Lasers Intenses et Applications (CELIA), UMR5107, F33405 Talence, France
| | - S Petit
- Université de Bordeaux-CNRS-CEA, Centre Lasers Intenses et Applications (CELIA), UMR5107, F33405 Talence, France
| | - O Smirnova
- Max-Born-Institute, Max-Born Straße 2A, 12489 Berlin, Germany
| | - Y Mairesse
- Université de Bordeaux-CNRS-CEA, Centre Lasers Intenses et Applications (CELIA), UMR5107, F33405 Talence, France
| | - M Y Ivanov
- Max-Born-Institute, Max-Born Straße 2A, 12489 Berlin, Germany
- Department of Physics, Humboldt University, Newtonstraße 15, D-12489 Berlin, Germany
- Blackett Laboratory, Imperial College London, SW7 2AZ London, United Kingdom
| |
Collapse
|
6
|
Bouzid D, Hingrat QL, Salipante F, Ferré V, Chevalier T, Timsit J, Descamps D, Visseaux B, Loubet P. Concordance de la détection des virus respiratoires sur écouvillonnage nasopharyngé et lavage broncho-alvéolaire chez l'adulte admis pour une suspicion de pneumonie. MÉDECINE ET MALADIES INFECTIEUSES FORMATION 2022. [PMCID: PMC9152505 DOI: 10.1016/j.mmifmc.2022.03.238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Introduction A ce jour, peu de données sont disponibles sur la concordance de la détection des virus respiratoires (en dehors du SARS-CoV2) entre le prélèvement nasopharyngé (NP) et le lavage broncho-alvéolaire (LBA) chez l'adulte. L'objectif de cette étude était de décrire la concordance de leurs résultats. Matériels et méthodes Une analyse rétrospective monocentrique a été réalisée à l'aide des données de 276 adultes suspects de pneumonie et testés par PCR multiplex dans le NP et le LBA à 24 heures d'intervalle. Résultats Les patients étaient majoritairement des hommes (65 %), avec un âge médian de 60 ans[IQR : 50,9-67,8]. 169 patients (61 %) ont été admis en réanimation Nous avons détecté au moins un virus respiratoire dans 95 NP (34 %) et dans 80 BAL (29 %). Comparé au LBA, le NP avait une sensibilité de 71,6 % et une spécificité de 93,4 % et un coefficient Kappa de 0,67. Le même agent pathogène ou combinaison d'agents pathogènes a été observé chez 84 % des patients positifs à la fois sur le NP et le LBA. La grippe B, le parainfluenza, les coronavirus HKU1, NL63, 229E présentaient la concordance la plus élevée (100 %) entre le NP et la LBA, tandis que le coronavirus OC43 et le rhinovirus présentaient la concordance la plus faible (33 % et 67 %, respectivement).Nous avons observé que les patients atteints d'une maladie respiratoire chronique ont une plus faible concordance entre le NP et LBA avec un OR ajusté à 0,5, IC 95 % (0,25-0,97), p = 0,043. Conclusion Dans ce travai, Il y a une bonne concordance entre le NP et le LBA dans la détection des virus respiratoires chez les patients consultant avec une suspicion de pneumonie. Néanmoins, ces données encouragent toujours à réaliser un LBA lorsque cela est possible afin d'obtenir un diagnostic étiologique plus précis. Aucun lien d'intérêt
Collapse
Affiliation(s)
- D. Bouzid
- CHU Bichat Claude Bernard, Paris, France
| | | | | | - V. Ferré
- CHU Bichat Claude Bernard, Paris, France
| | | | - J. Timsit
- CHU Bichat Claude Bernard, Paris, France
| | | | | | | |
Collapse
|
7
|
Ferré V, Brouk Z, Flament H, Kerneis C, Charpentier C, Verdonk C, Vicaut E, De Chaisemartin L, Descamps D, Houhou-Fidouh N, Dorent R. Humoral Response to SARS-CoV-2 mRNA Vaccine in Heart Transplant Recipients up to 4 Months After the Third Vaccine Injection. J Heart Lung Transplant 2022. [PMCID: PMC8988605 DOI: 10.1016/j.healun.2022.01.681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
8
|
Marquant Q, Laubreton D, Drajac C, Mathieu E, Bouguyon E, Noordine M, Remot A, Riffault S, Thomas M, Descamps D. La présence du microbiote permet de modérer la réponse immunitaire innée du poumon. Rev Mal Respir 2022. [DOI: 10.1016/j.rmr.2022.02.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
9
|
Mathieu E, Marquant Q, Descamps D, Riffault S, Saint-Criq V, Thomas M. Le poumon est sensible aux effets locaux et à distance des microbiotes. NUTR CLIN METAB 2021. [DOI: 10.1016/j.nupar.2021.04.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
10
|
Descamps D, Peres de Oliveira A, Gonnin L, Madrières S, Fix J, Drajac C, Marquant Q, Bouguyon E, Pietralunga V, Iha H, Morais Ventura A, Tangy F, Vidalain PO, Eléouët JF, Galloux M. Depletion of TAX1BP1 Amplifies Innate Immune Responses during Respiratory Syncytial Virus Infection. J Virol 2021; 95:e0091221. [PMID: 34431698 PMCID: PMC8549506 DOI: 10.1128/jvi.00912-21] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2021] [Accepted: 08/20/2021] [Indexed: 12/15/2022] Open
Abstract
Respiratory syncytial virus (RSV) is the main cause of acute respiratory infections in young children and also has a major impact on the elderly and immunocompromised people. In the absence of a vaccine or efficient treatment, a better understanding of RSV interactions with the host antiviral response during infection is needed. Previous studies revealed that cytoplasmic inclusion bodies (IBs), where viral replication and transcription occur, could play a major role in the control of innate immunity during infection by recruiting cellular proteins involved in the host antiviral response. We recently showed that the morphogenesis of IBs relies on a liquid-liquid-phase separation mechanism depending on the interaction between viral nucleoprotein (N) and phosphoprotein (P). These scaffold proteins are expected to play a central role in the recruitment of cellular proteins to IBs. Here, we performed a yeast two-hybrid screen using RSV N protein as bait and identified the cellular protein TAX1BP1 as a potential partner of this viral protein. This interaction was validated by pulldown and immunoprecipitation assays. We showed that TAX1BP1 suppression has only a limited impact on RSV infection in cell cultures. However, RSV replication is decreased in TAX1BP1-deficient (TAX1BP1 knockout [TAX1BP1KO]) mice, whereas the production of inflammatory and antiviral cytokines is enhanced. In vitro infection of wild-type or TAX1BP1KO alveolar macrophages confirmed that the innate immune response to RSV infection is enhanced in the absence of TAX1BP1. Altogether, our results suggest that RSV could hijack TAX1BP1 to restrain the host immune response during infection. IMPORTANCE Respiratory syncytial virus (RSV), which is the leading cause of lower respiratory tract illness in infants, remains a medical problem in the absence of a vaccine or efficient treatment. This virus is also recognized as a main pathogen in the elderly and immunocompromised people, and the occurrence of coinfections (with other respiratory viruses and bacteria) amplifies the risks of developing respiratory distress. In this context, a better understanding of the pathogenesis associated with viral respiratory infections, which depends on both viral replication and the host immune response, is needed. The present study reveals that the cellular protein TAX1BP1, which interacts with the RSV nucleoprotein N, participates in the control of the innate immune response during RSV infection, suggesting that the N-TAX1BP1 interaction represents a new target for the development of antivirals.
Collapse
Affiliation(s)
| | - Andressa Peres de Oliveira
- Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | - Lorène Gonnin
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Sarah Madrières
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Jenna Fix
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Carole Drajac
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Quentin Marquant
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Edwige Bouguyon
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | | | - Hidekatsu Iha
- Department of Infectious Diseases, Faculty of Medicine, Oita University Idaiga-oka, Hasama Yufu, Japan
| | - Armando Morais Ventura
- Departamento de Microbiologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
| | - Frédéric Tangy
- Unité de Génomique Virale et Vaccination, Institut Pasteur, CNRS UMR-3569, Paris, France
| | - Pierre-Olivier Vidalain
- Unité de Génomique Virale et Vaccination, Institut Pasteur, CNRS UMR-3569, Paris, France
- CIRI, Centre International de Recherche en Infectiologie, Université Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, Lyon, France
| | | | - Marie Galloux
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| |
Collapse
|
11
|
Veyrinas K, Vábek J, Valentin C, Descamps D, Péjot C, Burgy F, Constant E, Mével E, Catoire F. Spectral filtering of high-order harmonics via optics-free focusing. Opt Express 2021; 29:29813-29827. [PMID: 34614719 DOI: 10.1364/oe.436086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Accepted: 08/20/2021] [Indexed: 06/13/2023]
Abstract
Controlling the wavefront of an extreme ultraviolet (XUV) high-order harmonic beam during the generation process offers the capability of modifying the beam properties without resorting to any XUV optics. By characterizing the XUV intensity profile and wavefront, we quantitatively retrieve both the size and the position of the waist of each harmonic generated in an argon jet. We show that optics-free focusing can occur under specific generating conditions leading to XUV focii of micrometer size. We also demonstrate that each focus is located at distinct longitudinal positions. Using this remarkable XUV wavefront control combined with near focus spatial selection, we experimentally demonstrate efficient and adjustable spectral filtering of the XUV beam, along with a strong rejection of the fundamental beam, without using any XUV optics. The experimental results are compared with simulations providing the impact of the filtering on the temporal profile of the XUV field. It shows that the attosecond structure is preserved and that the beam is more homogeneous after the filtering, thereby reducing the longitudinal focii shift. This is a major step to achieve high XUV intensity and probing ultrafast processes with an improved resolution.
Collapse
|
12
|
Husain M, Rachline A, Cousien A, Rolland S, Ferre V, Wicky-Thisse M, Descamps D, Yazdanpanah Y, Charpentier C, Pasquet-Cadre A. Impact de la pandémie de COVID-19 sur les populations sans domicile fixe : résultats d’une cohorte fermée rétrospective (mars–mai 2020). Infect Dis Now 2021. [PMCID: PMC8327534 DOI: 10.1016/j.idnow.2021.06.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Introduction Les populations de sans domicile fixe ont un taux de mortalité supérieur à celui de la population générale. Ceci est en partie en lien avec des maladies chroniques non suivis, des problèmes d’addiction ainsi qu’une exposition plus forte aux maladies transmissibles, en particulier respiratoires. Nous avons réalisé une étude pour évaluer les taux d’attaque, d’hospitalisation et de mortalité liés à l’infection par le SARS-CoV-2 dans une population de résidents de centres d’hébergement pour sans-abri et du personnel à leur contact. Matériels et méthodes Une étude sérologique rétrospective a été réalisée sur l’ensemble des résidents et des membres du personnel de trois centres d’hébergement pour sans-abri entre mars et mai 2020 : 2 centres de lits halte soins santé (LHSS) et un dortoir de femmes. Nous avons inclus tous les adultes présents dans les centres d’hébergement ou décédés d’une infection avérée par le SARS-CoV-2. Les IgG anti-SARS-CoV-2 étaient détectés par le test ELISA « SARS-CoV-2 IgG Architect (Abbott) ». Un cas confirmé de SARS-CoV-2 était défini comme tout participant présentant une PCR ou une sérologie positive. Des sérologies de contrôle ont été prélevées quatre mois après la première sérologie positive. Résultats Nous avons inclus 100 résidents et 83 membres du personnel. Le taux de SARS-CoV-2 confirmé par PCR ou sérologie était de 72/100 (72,0 %) pour les résidents et de 17/83 (20,5 %) pour le personnel. Le taux d’hospitalisation chez les résidents était de 17/72 (25 %) et le taux de décès de 4/72 (5,6 %). Toutes les hospitalisations sauf une et tous les décès sont survenus chez des résidents des LHSS. Trente-quatre sur 68 (50 %) des résidents des LHSS présentaient au moins deux facteurs de risque de forme grave d’infection par le SARS-CoV-2. Les femmes hébergées dans le dortoir étaient plus jeunes, présentaient moins de comorbidité, avaient le taux d’attaque le plus élevé (90,6 %) et une morbidité-mortalité quasi nulle. Cinquante-deux sur 80 (63,4 %) des personnes ayant une première sérologie positive ont eu une sérologie de contrôle à 4 mois de la première sérologie et 8 mois environ de leur infection. Parmi eux, 44 (84,6 %) avaient conservé des sérologies positives. Conclusion Le taux d’attaque du SARS-CoV-2 était extrêmement élevé chez les résidents des centres d’hébergement pour sans-abri par rapport à la population générale. Le risque d’infection grave par le SARS-CoV-2 était fortement associé à la présence de comorbidités à un plus jeune âge. Cette population à risqué doit être considérée comme prioritaire dans les campagnes de vaccination dans l’accès aux logements individuels pour les plus vulnérables.
Collapse
|
13
|
Peiffer-Smadja N, Bridier-Nahmias A, Carpentier C, Garé M, Rioux C, Allemand A, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B. Émergence de variants E484 K suite à une monothérapie bamlanivimab chez des patients COVID-19 à haut risque d’évolution vers une forme sévère. Infect Dis Now 2021. [PMCID: PMC8327506 DOI: 10.1016/j.idnow.2021.06.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
Introduction En France, une Autorisation d’Utilisation Temporaire de cohorte (ATUc) a été délivrée le 27/02/2021 pour l’utilisation du bamlanivimab en monothérapie dans le traitement précoce (< 5 jours du début des symptômes) de patients adultes avec un COVID-19 léger à modéré confirmé par PCR et à haut risque d’évolution vers une forme sévère. Les patients concernés étaient les patients de > 80 ans ou les patients de < 80 ans immunodéprimés (transplantation, chimiothérapie, traitement immunosuppresseur). Le risque d’émergence de variants potentiellement résistants à un monothérapie par anticorps monoclonal anti-Spike, en particulier les variants E484 K, avait été pris en compte lors de l’ATUc. Cependant, le bénéfice potentiel de ces traitements chez les patients à haut risque a été considéré comme supérieur au risque. Ici nous décrivons 6 patients ayant reçu de ce traitement, leur évolution et l’émergence de mutations de résistance sous pression de sélection. Matériels et méthodes Il s’agit d’une étude unicentrique en centre hospitalier universitaire. Le bamlanivimab a été administré à une dose unique de 700 mg en injection IV d’une heure chez 6 patients qui ont accepté d’utiliser le traitement dans le cadre de l’ATUc. Le suivi virologique des patients a consisté en un test RT-qPCR itératif réalisé le jour de la perfusion ou la veille, à J3 ± 1, à J5 ± 1, à J7 ± 1 puis tous les 3 jours jusqu’à ce que la PCR soit négative. La sélection de mutation de résistance a été vérifiée par séquençage du génome complet du SARS-CoV-2 chez tous les patients. Résultats Les six hommes traités avaient un âge médian de 65 ans (extrêmes 35-97), plus de 3 comorbidités à haut risque d’évolution vers une forme sévère et 5 étaient infectés par un variant UK (N501Y.V1, B.1.1.7). Le traitement a été administré dans les 4 jours suivant l’apparition des symptômes (médiane 2 jours). Les 6 patients ont eu une évolution clinique favorable, deux ont eu besoin d’oxygène au débit maximal de 4 L/min. Aucun patient n’a eu besoin d’oxygénothérapie haut débit, d’une ventilation non invasive ou d’une ventilation invasive. À J20 après l’administration, un seul présentait une PCR nasopharyngée négative et 5 présentaient l’apparition d’une mutation E484 K à différents moments après l’administration (J6, J7, J12, J14 et J26). Conclusion Chez ces patients à très haut risque d’évolution vers une forme sévère, la sélection de la mutation E484 K après administration de bamlanivimab en monothérapie était très fréquente et bien plus importante qu’observée dans les premiers essais cliniques. Ceci peut être expliqué en partie par l’infection par un variant UK pour 5/6 patients décrits ici. L’émergence de résistance lors des bithérapies devra être suivi attentivement, notamment avec l’émergence des nouveaux variants.
Collapse
|
14
|
Marquant Q, Laubreton D, Drajac C, Mathieu E, Bouguyon E, Noordine ML, Remot A, Riffault S, Thomas M, Descamps D. The microbiota plays a critical role in the reactivity of lung immune components to innate ligands. FASEB J 2021; 35:e21348. [PMID: 33715218 DOI: 10.1096/fj.202002338r] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 12/18/2020] [Accepted: 12/22/2020] [Indexed: 12/12/2022]
Abstract
The gut microbiota contributes to shaping efficient and safe immune defenses in the gut. However, little is known about the role of the gut and/or lung microbiota in the education of pulmonary innate immune responses. Here, we tested whether the endogenous microbiota in general can modulate the reactivity of pulmonary tissue to pathogen stimuli by comparing the response of specific-pathogen-free (SPF) and germ-free (GF) mice. Thus, we observed earlier and greater inflammation in the pulmonary compartment of GF mice than that of SPF mice after intranasal instillation to lipopolysaccharide (LPS), a component of Gram-negative bacteria. Toll-like receptor 4 (TLR4) was more abundantly expressed in the lungs of GF mice than those of SPF mice at steady state, which could predispose the innate immunity of GF mice to strongly react to the environmental stimuli. Lung explants were stimulated with different TLR agonists or infected with the human airways pathogen, respiratory syncytial virus (RSV), resulting in greater inflammation under almost all conditions for the GF explants. Finally, alveolar macrophages (AM) from GF mice presented a higher innate immune response upon RSV infection than those of SPF mice. Overall, these data suggest that the presence of microbiota in SPF mice induced a process of innate immune tolerance in the lungs by a mechanism which remains to be elucidated. Our study represents a step forward to establishing the link between the microbiota and the immune reactivity of the lungs.
Collapse
Affiliation(s)
- Quentin Marquant
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Daphné Laubreton
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Carole Drajac
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Elliot Mathieu
- Université Paris-Saclay, INRAE, Micalis, Jouy-en-Josas, France
| | - Edwige Bouguyon
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | | | - Aude Remot
- Université de Tours, INRAE, ISP, Tours, France
| | - Sabine Riffault
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Muriel Thomas
- Université Paris-Saclay, INRAE, Micalis, Jouy-en-Josas, France
| | | |
Collapse
|
15
|
Remot A, Carreras F, Coupé A, Doz-Deblauwe É, Boschiroli ML, Browne JA, Marquant Q, Descamps D, Archer F, Aseffa A, Germon P, Gordon SV, Winter N. Mycobacterial Infection of Precision-Cut Lung Slices Reveals Type 1 Interferon Pathway Is Locally Induced by Mycobacterium bovis but Not M. tuberculosis in a Cattle Breed. Front Vet Sci 2021; 8:696525. [PMID: 34307535 PMCID: PMC8299756 DOI: 10.3389/fvets.2021.696525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Accepted: 06/02/2021] [Indexed: 11/13/2022] Open
Abstract
Tuberculosis exacts a terrible toll on human and animal health. While Mycobacterium tuberculosis (Mtb) is restricted to humans, Mycobacterium bovis (Mb) is present in a large range of mammalian hosts. In cattle, bovine TB (bTB) is a noticeable disease responsible for important economic losses in developed countries and underestimated zoonosis in the developing world. Early interactions that take place between mycobacteria and the lung tissue early after aerosol infection govern the outcome of the disease. In cattle, these early steps remain poorly characterized. The precision-cut lung slice (PCLS) model preserves the structure and cell diversity of the lung. We developed this model in cattle in order to study the early lung response to mycobacterial infection. In situ imaging of PCLS infected with fluorescent Mb revealed bacilli in the alveolar compartment, in adjacent or inside alveolar macrophages, and in close contact with pneumocytes. We analyzed the global transcriptional lung inflammation signature following infection of PCLS with Mb and Mtb in two French beef breeds: Blonde d'Aquitaine and Charolaise. Whereas, lungs from the Blonde d'Aquitaine produced high levels of mediators of neutrophil and monocyte recruitment in response to infection, such signatures were not observed in the Charolaise in our study. In the Blonde d'Aquitaine lung, whereas the inflammatory response was highly induced by two Mb strains, AF2122 isolated from cattle in the UK and Mb3601 circulating in France, the response against two Mtb strains, H37Rv, the reference laboratory strain, and BTB1558, isolated from zebu in Ethiopia, was very low. Strikingly, the type I interferon pathway was only induced by Mb but not Mtb strains, indicating that this pathway may be involved in mycobacterial virulence and host tropism. Hence, the PCLS model in cattle is a valuable tool to deepen our understanding of early interactions between lung host cells and mycobacteria. It revealed striking differences between cattle breeds and mycobacterial strains. This model could help in deciphering biomarkers of resistance vs. susceptibility to bTB in cattle as such information is still critically needed for bovine genetic selection programs and would greatly help the global effort to eradicate bTB.
Collapse
Affiliation(s)
- Aude Remot
- INRAE, Université de Tours, Nouzilly, France
| | | | | | | | - Maria L Boschiroli
- Paris-Est University, National Reference Laboratory for Tuberculosis, Animal Health Laboratory, Anses, Maisons-Alfort, France
| | - John A Browne
- UCD School of Agriculture and Food Science, University College Dublin, Dublin, Ireland
| | | | | | - Fabienne Archer
- INRAE, UMR754, Viral Infections and Comparative Pathology, IVPC, Univ Lyon, Université Claude Bernard Lyon 1, EPHE, Lyon, France
| | - Abraham Aseffa
- Armauer Hansen Research Institute, Addis Ababa, Ethiopia
| | | | - Stephen V Gordon
- UCD School of Veterinary Medicine and UCD Conway Institute, University College Dublin, Dublin, Ireland
| | | |
Collapse
|
16
|
Bachelard A, Isernia V, Vallois D, Le Gac S, Chalal L, Landman R, Damond F, Descamps D, Yazdanpanah Y, Peytavin G, Ghosn J. Efficacy and tolerability of combined antiretroviral treatment with bictegravir/emtricitabine/tenofovir alafenamide initiated at the time of primary HIV infection. J Antimicrob Chemother 2021; 76:2484-2485. [PMID: 34109414 DOI: 10.1093/jac/dkab192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- A Bachelard
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France
| | - V Isernia
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France
| | - D Vallois
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France
| | - S Le Gac
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France
| | - L Chalal
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France
| | - R Landman
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France.,IAME-UMR 1137 INSERM, Université de Paris, Paris, France
| | - F Damond
- AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, Paris, France
| | - D Descamps
- IAME-UMR 1137 INSERM, Université de Paris, Paris, France.,AP-HP, Hospital Bichat-Claude Bernard, Virology Laboratory, Paris, France
| | - Y Yazdanpanah
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France.,IAME-UMR 1137 INSERM, Université de Paris, Paris, France
| | - G Peytavin
- IAME-UMR 1137 INSERM, Université de Paris, Paris, France.,AP-HP, Hospital Bichat-Claude Bernard, Pharmacology-Toxicology Laboratory, Paris, France
| | - J Ghosn
- AP-HP, Hospital Bichat-Claude-Bernard, Infectious and Tropical Diseases, Paris, France.,IAME-UMR 1137 INSERM, Université de Paris, Paris, France
| |
Collapse
|
17
|
Jacque E, Chottin C, Laubreton D, Nogre M, Ferret C, de Marcos S, Baptista L, Drajac C, Mondon P, De Romeuf C, Rameix-Welti MA, Eléouët JF, Chtourou S, Riffault S, Perret G, Descamps D. Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis. Front Immunol 2021; 12:683902. [PMID: 34163482 PMCID: PMC8215542 DOI: 10.3389/fimmu.2021.683902] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 05/17/2021] [Indexed: 11/23/2022] Open
Abstract
Respiratory syncytial virus (RSV) is a public health concern that causes acute lower respiratory tract infection. So far, no vaccine candidate under development has reached the market and the only licensed product to prevent RSV infection in at-risk infants and young children is a monoclonal antibody (Synagis®). Polyclonal human anti-RSV hyper-immune immunoglobulins (Igs) have also been used but were superseded by Synagis® owing to their low titer and large infused volume. Here we report a new drug class of immunoglobulins, derived from human non hyper-immune plasma that was generated by an innovative bioprocess, called Ig cracking, combining expertises in plasma-derived products and affinity chromatography. By using the RSV fusion protein (F protein) as ligand, the Ig cracking process provided a purified and concentrated product, designated hyper-enriched anti-RSV IgG, composed of at least 15-20% target-specific-antibodies from normal plasma. These anti-RSV Ig displayed a strong in vitro neutralization effect on RSV replication. Moreover, we described a novel prophylactic strategy based on local nasal administration of this unique hyper-enriched anti-RSV IgG solution using a mouse model of infection with bioluminescent RSV. Our results demonstrated that very low doses of hyper-enriched anti-RSV IgG can be administered locally to ensure rapid and efficient inhibition of virus infection. Thus, the general hyper-enriched Ig concept appeared a promising approach and might provide solutions to prevent and treat other infectious diseases.
Collapse
Affiliation(s)
| | - Claire Chottin
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | - Daphné Laubreton
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | | | - Cécile Ferret
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | | | | | - Carole Drajac
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | | | | | - Marie-Anne Rameix-Welti
- Université Paris-Saclay, UVSQ, Inserm, Infection et inflammation, U1173, Montigny-Le-Bretonneux, France.,AP-HP, Hôpital Ambroise Paré, Laboratoire de Microbiologie, Boulogne-Billancourt, France
| | | | | | - Sabine Riffault
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jouy-en-Josas, France
| | | | | |
Collapse
|
18
|
Hort O, Dubrouil A, Khokhlova MA, Descamps D, Petit S, Burgy F, Mével E, Constant E, Strelkov VV. High-order parametric generation of coherent XUV radiation. Opt Express 2021; 29:5982-5992. [PMID: 33726129 DOI: 10.1364/oe.418449] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 02/01/2021] [Indexed: 06/12/2023]
Abstract
Extreme ultraviolet (XUV) radiation finds numerous applications in spectroscopy. When the XUV light is generated via high-order harmonic generation (HHG), it may be produced in the form of attosecond pulses, allowing access to unprecedented ultrafast phenomena. However, the HHG efficiency remains limited. Here we present an observation of a new regime of coherent XUV emission which has a potential to provide higher XUV intensity, vital for applications. We explain the process by high-order parametric generation, involving the combined emission of THz and XUV photons, where the phase matching is very robust against ionization. This introduces a way to use higher-energy driving pulses, thus generating more XUV photons.
Collapse
|
19
|
Cotte L, Hocqueloux L, Lefebvre M, Pradat P, Bani-Sadr F, Huleux T, Poizot-Martin I, Pugliese P, Rey D, Cabié A, Chirouze C, Drobacheff-Thiébaut C, Foltzer A, Bouiller K, Hustache-Mathieu L, Lepiller Q, Bozon F, Babre O, Brunel AS, Muret P, Chevalier E, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Aumeran C, Baud O, Corbin V, Goncalvez E, Mirand A, brebion A, Henquell C, Lamaury I, Fabre I, Curlier E, Ouissa R, Herrmann-Storck C, Tressieres B, Receveur MC, Boulard F, Daniel C, Clavel C, Roger PM, Markowicz S, Chellum Rungen N, Merrien D, Perré P, Guimard T, Bollangier O, Leautez S, Morrier M, Laine L, Boucher D, Point P, Cotte L, Ader F, Becker A, Boibieux A, Brochier C, Brunel-Dalmas F, Cannesson O, Chiarello P, Chidiac C, Degroodt S, Ferry T, Godinot M, Livrozet JM, Makhloufi D, Miailhes P, Perpoint T, Perry M, Pouderoux C, Roux S, Triffault-Fillit C, Valour F, Charre C, Icard V, Tardy JC, Trabaud MA, Ravaux I, Ménard A, Belkhir AY, Colson P, Dhiver C, Madrid A, Martin-Degioanni M, Meddeb L, Mokhtari M, Motte A, Raoux A, Toméi C, Tissot-Dupont H, Poizot-Martin I, Brégigeon S, Zaegel-Faucher O, Obry-Roguet V, Laroche H, Orticoni M, Soavi MJ, Ressiot E, Ducassou MJ, Jaquet I, Galie S, Colson H, Ritleng AS, Ivanova A, Debreux C, Lions C, Rojas-Rojas T, Cabié A, Abel S, Bavay J, Bigeard B, Cabras O, Cuzin L, Dupin de Majoubert R, Fagour L, Guitteaud K, Marquise A, Najioullah F, Pierre-François S, Pasquier J, Richard P, Rome K, Turmel JM, Varache C, Atoui N, Bistoquet M, Delaporte E, Le Moing V, Makinson A, Meftah N, Merle de Boever C, Montes B, Montoya Ferrer A, Tuaillon E, Reynes J, Lefèvre B, Jeanmaire E, Hénard S, Frentiu E, Charmillon A, Legoff A, Tissot N, André M, Boyer L, Bouillon MP, Delestan M, Goehringer F, Bevilacqua S, Rabaud C, May T, Raffi F, Allavena C, Aubry O, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-Cartier C, Deschanvres C, Gaborit BJ, Grégoire A, Grégoire M, Grossi O, Guéry R, Jovelin T, Lefebvre M, Le Turnier P, Lecomte R, Morineau P, Reliquet V, Sécher S, Cavellec M, Paredes E, Soria A, Ferré V, André-Garnier E, Rodallec A, Pugliese P, Breaud S, Ceppi C, Chirio D, Cua E, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Garraffo R, Michelangeli C, Mondain V, Naqvi A, Oran N, Perbost I, Carles M, Klotz C, Maka A, Pradier C, Prouvost-Keller B, Risso K, Rio V, Rosenthal E, Touitou I, Wehrlen-Pugliese S, Zouzou G, Hocqueloux L, Prazuck T, Gubavu C, Sève A, Giaché S, Rzepecki V, Colin M, Boulard C, Thomas G, Cheret A, Goujard C, Quertainmont Y, Teicher E, Lerolle N, Jaureguiberry S, Colarino R, Deradji O, Castro A, Barrail-Tran A, Yazdanpanah Y, Landman R, Joly V, Ghosn J, Rioux C, Lariven S, Gervais A, Lescure FX, Matheron S, Louni F, Julia Z, Le GAC S, Charpentier C, Descamps D, Peytavin G, Duvivier C, Aguilar C, Alby-Laurent F, Amazzough K, Benabdelmoumen G, Bossi P, Cessot G, Charlier C, Consigny PH, Jidar K, Lafont E, Lanternier F, Leporrier J, Lortholary O, Louisin C, Lourenco J, Parize P, Pilmis B, Rouzaud C, Touam F, Valantin MA, Tubiana R, Agher R, Seang S, Schneider L, PaLich R, Blanc C, Katlama C, Bani-Sadr F, Berger JL, N’Guyen Y, Lambert D, Kmiec I, Hentzien M, Brunet A, Romaru J, Marty H, Brodard V, Arvieux C, Tattevin P, Revest M, Souala F, Baldeyrou M, Patrat-Delon S, Chapplain JM, Benezit F, Dupont M, Poinot M, Maillard A, Pronier C, Lemaitre F, Morlat C, Poisson-Vannier M, Jovelin T, Sinteff JP, Gagneux-Brunon A, Botelho-Nevers E, Frésard A, Ronat V, Lucht F, Rey D, Fischer P, Partisani M, Cheneau C, Priester M, Mélounou C, Bernard-Henry C, de Mautort E, Fafi-Kremer S, Delobel P, Alvarez M, Biezunski N, Debard A, Delpierre C, Gaube G, Lansalot P, Lelièvre L, Marcel M, Martin-Blondel G, Piffaut M, Porte L, Saune K, Robineau O, Ajana F, Aïssi E, Alcaraz I, Alidjinou E, Baclet V, Bocket L, Boucher A, Digumber M, Huleux T, Lafon-Desmurs B, Meybeck A, Pradier M, Tetart M, Thill P, Viget N, Valette M. Microelimination or Not? The Changing Epidemiology of Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in France 2012–2018. Clin Infect Dis 2021; 73:e3266-e3274. [DOI: 10.1093/cid/ciaa1940] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2020] [Accepted: 01/01/2021] [Indexed: 01/15/2023] Open
Abstract
Abstract
Background
The arrival of highly effective, well-tolerated, direct-acting antiviral agents (DAA) led to a dramatic decrease in hepatitis C virus (HCV) prevalence. Human immunodeficiency virus (HIV)-HCV–coinfected patients are deemed a priority population for HCV elimination, while a rise in recently acquired HCV infections in men who have sex with men (MSM) has been described. We describe the variations in HIV-HCV epidemiology in the French Dat’AIDS cohort.
Methods
This was a retrospective analysis of a prospective cohort of persons living with HIV (PLWH) from 2012 to 2018. We determined HCV prevalence, HCV incidence, proportion of viremic patients, treatment uptake, and mortality rate in the full cohort and by HIV risk factors.
Results
From 2012 to 2018, 50 861 PLWH with a known HCV status were followed up. During the period, HCV prevalence decreased from 15.4% to 13.5%. HCV prevalence among new HIV cases increased from 1.9% to 3.5% in MSM but remained stable in other groups. Recently acquired HCV incidence increased from 0.36/100 person-years to 1.25/100 person-years in MSM. The proportion of viremic patients decreased from 67.0% to 8.9%. MSM became the first group of viremic patients in 2018 (37.9%). Recently acquired hepatitis represented 59.2% of viremic MSM in 2018. DAA treatment uptake increased from 11.4% to 61.5%. More treatments were initiated in MSM in 2018 (41.2%) than in intravenous drug users (35.6%). In MSM, treatment at the acute phase represented 30.0% of treatments in 2018.
Conclusions
A major shift in HCV epidemiology was observed in PLWH in France from 2012 to 2018, leading to a unique situation in which the major group of HCV transmission in 2018 was MSM.
Clinical Trials Registration. NCT02898987.
Collapse
Affiliation(s)
- Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) U1052, Lyon, France
| | - Laurent Hocqueloux
- Department of Infectious Diseases, Centre Hospitalier Régional d’Orléans – La Source, Orléans, France
| | - Maeva Lefebvre
- Department of Infectious Diseases, Centre Hospitalier Universitaire Hôtel-Dieu, Nantes; Centre d’Investigation Clinique (CIC) 1413, INSERM, Nantes, France
| | - Pierre Pradat
- Center for Clinical Research, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Clinical Immunology and Infectious Diseases, Robert Debré Hospital, University Hospital, Reims, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Isabelle Poizot-Martin
- Immuno-Hematology Clinic, Assistance Publique–Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, Aix-MarseilleUniversity–Inserm–Institut de Recherche pour le Développement (IRD), Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, Marseille, France
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l’Archet, Nice, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg
| | - André Cabié
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Martinique, Fort de France, Université des Antilles EA4537, Fort de France, INSERM CIC1424, Fort-de-France, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Descamps D, Evnouchidou I, Caillens V, Drajac C, Riffault S, van Endert P, Saveanu L. The Role of Insulin Regulated Aminopeptidase in Endocytic Trafficking and Receptor Signaling in Immune Cells. Front Mol Biosci 2020; 7:583556. [PMID: 33195428 PMCID: PMC7606930 DOI: 10.3389/fmolb.2020.583556] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 09/25/2020] [Indexed: 12/15/2022] Open
Abstract
Insulin regulated aminopeptidase (IRAP) is a type II transmembrane protein with broad tissue distribution initially identified as a major component of Glut4 storage vesicles (GSV) in adipocytes. Despite its almost ubiquitous expression, IRAP had been extensively studied mainly in insulin responsive cells, such as adipocytes and muscle cells. In these cells, the enzyme displays a complex intracellular trafficking pattern regulated by insulin. Early studies using fusion proteins joining the IRAP cytosolic domain to various reporter proteins, such as GFP or the transferrin receptor (TfR), showed that the complex and regulated trafficking of the protein depends on its cytosolic domain. This domain contains several motifs involved in IRAP trafficking, as demonstrated by mutagenesis studies. Also, proteomic studies and yeast two-hybrid experiments showed that the IRAP cytosolic domain engages in multiple protein interactions with cytoskeleton components and vesicular trafficking adaptors. These findings led to the hypothesis that IRAP is not only a cargo of GSV but might be a part of the sorting machinery that controls GSV dynamics. Recent work in adipocytes, immune cells, and neurons confirmed this hypothesis and demonstrated that IRAP has a dual function. Its carboxy-terminal domain located inside endosomes is responsible for the aminopeptidase activity of the enzyme, while its amino-terminal domain located in the cytosol functions as an endosomal trafficking adaptor. In this review, we recapitulate the published protein interactions of IRAP and summarize the increasing body of evidence indicating that IRAP plays a role in intracellular trafficking of several proteins. We describe the impact of IRAP deletion or depletion on endocytic trafficking and the consequences on immune cell functions. These include the ability of dendritic cells to cross-present antigens and prime adaptive immune responses, as well as the control of innate and adaptive immune receptor signaling and modulation of inflammatory responses.
Collapse
Affiliation(s)
| | - Irini Evnouchidou
- Université de Paris, Centre de recherche sur l'inflammation, INSERM U1149, CNRS ERL8252, Paris, France.,Inovarion, Paris, France
| | - Vivien Caillens
- Université de Paris, Centre de recherche sur l'inflammation, INSERM U1149, CNRS ERL8252, Paris, France
| | - Carole Drajac
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jou-en-Josas, France
| | - Sabine Riffault
- Université Paris-Saclay, INRAE, UVSQ, VIM, Jou-en-Josas, France
| | - Peter van Endert
- Université de Paris, Centre de recherche sur l'inflammation, INSERM U1149, CNRS ERL8252, Paris, France.,Université de Paris, INSERM Unité 1151, CNRS UMR 8253, Paris, France.,Service d'immunologie biologique, AP-HP, Hôpital Necker, Paris, France
| | - Loredana Saveanu
- Université de Paris, Centre de recherche sur l'inflammation, INSERM U1149, CNRS ERL8252, Paris, France
| |
Collapse
|
21
|
Comby A, Beaulieu S, Constant E, Descamps D, Petit S, Mairesse Y. Absolute gas density profiling in high-order harmonic generation: erratum. Opt Express 2020; 28:32105. [PMID: 33115172 DOI: 10.1364/oe.409445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Indexed: 06/11/2023]
Abstract
In this erratum, we correct two numerical errors due to conversion mistakes from our previous published manuscript [Opt. Express 26, 6001 (2018)]. In the original manuscript, the two errors compensated each other such that the conclusions remain perfectly unchanged.
Collapse
|
22
|
Fedorov N, Beaulieu S, Belsky A, Blanchet V, Bouillaud R, De Anda Villa M, Filippov A, Fourment C, Gaudin J, Grisenti RE, Lamour E, Lévy A, Macé S, Mairesse Y, Martin P, Martinez P, Noé P, Papagiannouli I, Patanen M, Petit S, Vernhet D, Veyrinas K, Descamps D. Aurore: A platform for ultrafast sciences. Rev Sci Instrum 2020; 91:105104. [PMID: 33138551 DOI: 10.1063/5.0012485] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Accepted: 09/16/2020] [Indexed: 06/11/2023]
Abstract
We present the Aurore platform for ultrafast sciences. This platform is based on a unique 20 W, 1 kHz, 26 fs Ti:sapphire laser system designed for reliable operation and high intensity temporal contrast. The specific design ensures the high stability in terms of pulse duration, energy, and beam pointing necessary for extended experimental campaigns. The laser supplies 5 different beamlines, all dedicated to a specific field: attosecond science (Aurore 1), ultrafast phase transitions in solids (Aurore 2 and 3), ultrafast luminescence in solids (Aurore 4), and femtochemistry (Aurore 5). The technical specifications of these five beamlines are described in detail, and examples of the recent results are given.
Collapse
Affiliation(s)
- N Fedorov
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - S Beaulieu
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - A Belsky
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - V Blanchet
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - R Bouillaud
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - M De Anda Villa
- Sorbonne Université, CNRS, UMR 7588, Institut des Nanosciences de Paris, INSP, Campus Pierre et Marie Curie, F-75252 Paris Cedex 05, France
| | - A Filippov
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - C Fourment
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - J Gaudin
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - R E Grisenti
- Institut für Kernphysik, J. W. Goethe Universität, Max von Laue Str. 1, 60438 Frankfurt am Main, Germany
| | - E Lamour
- Sorbonne Université, CNRS, UMR 7588, Institut des Nanosciences de Paris, INSP, Campus Pierre et Marie Curie, F-75252 Paris Cedex 05, France
| | - A Lévy
- Sorbonne Université, CNRS, UMR 7588, Institut des Nanosciences de Paris, INSP, Campus Pierre et Marie Curie, F-75252 Paris Cedex 05, France
| | - S Macé
- Sorbonne Université, CNRS, UMR 7588, Institut des Nanosciences de Paris, INSP, Campus Pierre et Marie Curie, F-75252 Paris Cedex 05, France
| | - Y Mairesse
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - P Martin
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - P Martinez
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - P Noé
- Université Grenoble Alpes, CEA-LETI, 17 rue des Martyrs, F-38054 Grenoble Cedex 9, France
| | - I Papagiannouli
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - M Patanen
- Nano and Molecular Systems Research Unit, Faculty of Science, University of Oulu, P.O. Box 3000, FI-90014 Oulu, Finland
| | - S Petit
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - D Vernhet
- Sorbonne Université, CNRS, UMR 7588, Institut des Nanosciences de Paris, INSP, Campus Pierre et Marie Curie, F-75252 Paris Cedex 05, France
| | - K Veyrinas
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| | - D Descamps
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F-33405 Talence, France
| |
Collapse
|
23
|
Nguyen S, Wallard P, Oddoux O, Descamps D. Caractéristiques cliniques et pronostiques des bactériémies à Staphylococcus aureus dans un centre hospitalier général. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
24
|
Wallard P, Nguyen S, Robineau O, Descamps D, Senneville E. Prise en charge de l’ostéite du pied diabétique par chirurgie conservatrice. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
25
|
Laubreton D, Drajac C, Eléouët JF, Rameix-Welti MA, Lo-Man R, Riffault S, Descamps D. Regulatory B Lymphocytes Colonize the Respiratory Tract of Neonatal Mice and Modulate Immune Responses of Alveolar Macrophages to RSV Infection in IL-10-Dependant Manner. Viruses 2020; 12:v12080822. [PMID: 32751234 PMCID: PMC7472339 DOI: 10.3390/v12080822] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 07/24/2020] [Accepted: 07/25/2020] [Indexed: 12/11/2022] Open
Abstract
Respiratory syncytial virus (RSV) is the prevalent pathogen of lower respiratory tract infections in children. The presence of neonatal regulatory B lymphocytes (nBreg) has been associated with a poor control of RSV infection in human newborns and with bronchiolitis severity. So far, little is known about how nBreg may contribute to neonatal immunopathology to RSV. We tracked nBreg in neonatal BALB/c mice and we investigated their impact on lung innate immunity, especially their crosstalk with alveolar macrophages (AMs) upon RSV infection. We showed that the colonization by nBreg during the first week of life is a hallmark of neonatal lung whereas this population is almost absent in adult lung. This particular period of age when nBreg are abundant corresponds to the same period when RSV replication in lungs fails to generate a type-I interferons (IFN-I) response and is not contained. When neonatal AMs are exposed to RSV in vitro, they produce IFN-I that in turn enhances IL-10 production by nBreg. IL-10 reciprocally can decrease IFN-I secretion by AMs. Thus, our work identified nBreg as an important component of neonatal lungs and pointed out new immunoregulatory interactions with AMs in the context of RSV infection.
Collapse
Affiliation(s)
- Daphné Laubreton
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France; (D.L.); (C.D.); (J.-F.E.)
| | - Carole Drajac
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France; (D.L.); (C.D.); (J.-F.E.)
| | - Jean-François Eléouët
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France; (D.L.); (C.D.); (J.-F.E.)
| | - Marie-Anne Rameix-Welti
- Université Paris-Saclay, UVSQ, Inserm, Infection et Inflammation, U1173, 78180 Montigny-Le-Bretonneux, France;
- Laboratoire de Microbiologie, Hôpital Ambroise Paré, AP-HP, 92100 Boulogne-Billancourt, France
| | - Richard Lo-Man
- The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology and Immunology, Unit Immunity and Pediatric Infectious Diseases, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China;
- University of Chinese Academy of Sciences, Beijing 100039, China
| | - Sabine Riffault
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France; (D.L.); (C.D.); (J.-F.E.)
- Correspondence: (S.R.); (D.D.); Tel.: +(33)-01-34-65-26-20 (S.R.); +(33)-01-34-65-26-10 (D.D.)
| | - Delphyne Descamps
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France; (D.L.); (C.D.); (J.-F.E.)
- Correspondence: (S.R.); (D.D.); Tel.: +(33)-01-34-65-26-20 (S.R.); +(33)-01-34-65-26-10 (D.D.)
| |
Collapse
|
26
|
Sesterhenn F, Yang C, Bonet J, Cramer JT, Wen X, Wang Y, Chiang CI, Abriata LA, Kucharska I, Castoro G, Vollers SS, Galloux M, Dheilly E, Rosset S, Corthésy P, Georgeon S, Villard M, Richard CA, Descamps D, Delgado T, Oricchio E, Rameix-Welti MA, Más V, Ervin S, Eléouët JF, Riffault S, Bates JT, Julien JP, Li Y, Jardetzky T, Krey T, Correia BE. De novo protein design enables the precise induction of RSV-neutralizing antibodies. Science 2020; 368:eaay5051. [PMID: 32409444 PMCID: PMC7391827 DOI: 10.1126/science.aay5051] [Citation(s) in RCA: 109] [Impact Index Per Article: 27.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Revised: 01/30/2020] [Accepted: 04/08/2020] [Indexed: 12/27/2022]
Abstract
De novo protein design has been successful in expanding the natural protein repertoire. However, most de novo proteins lack biological function, presenting a major methodological challenge. In vaccinology, the induction of precise antibody responses remains a cornerstone for next-generation vaccines. Here, we present a protein design algorithm called TopoBuilder, with which we engineered epitope-focused immunogens displaying complex structural motifs. In both mice and nonhuman primates, cocktails of three de novo-designed immunogens induced robust neutralizing responses against the respiratory syncytial virus. Furthermore, the immunogens refocused preexisting antibody responses toward defined neutralization epitopes. Overall, our design approach opens the possibility of targeting specific epitopes for the development of vaccines and therapeutic antibodies and, more generally, will be applicable to the design of de novo proteins displaying complex functional motifs.
Collapse
Affiliation(s)
- Fabian Sesterhenn
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Che Yang
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Jaume Bonet
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Johannes T Cramer
- Institute of Virology, Hannover Medical School, Hannover 30625, Germany
| | - Xiaolin Wen
- Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Yimeng Wang
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA
| | - Chi-I Chiang
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA
| | - Luciano A Abriata
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Iga Kucharska
- Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, Ontario M5G 0A4, Canada
- Departments of Biochemistry and Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada
| | - Giacomo Castoro
- Institute of Virology, Hannover Medical School, Hannover 30625, Germany
| | - Sabrina S Vollers
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Marie Galloux
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France
| | - Elie Dheilly
- Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
| | - Stéphane Rosset
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Patricia Corthésy
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Sandrine Georgeon
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | - Mélanie Villard
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| | | | - Delphyne Descamps
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France
| | - Teresa Delgado
- Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain
| | - Elisa Oricchio
- Swiss Institute for Experimental Cancer Research, School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland
| | | | - Vicente Más
- Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Madrid, Spain
| | - Sean Ervin
- Wake Forest Baptist Medical Center, Winston Salem, NC 27157, USA
| | | | - Sabine Riffault
- Université Paris-Saclay, INRAE, UVSQ, VIM, 78350 Jouy-en-Josas, France
| | - John T Bates
- University of Mississippi Medical Center, Jackson, MS 39216, USA
| | - Jean-Philippe Julien
- Program in Molecular Medicine, Hospital for Sick Children Research Institute, Toronto, Ontario M5G 0A4, Canada
- Departments of Biochemistry and Immunology, University of Toronto, Toronto, Ontario M5S 1A8, Canada
| | - Yuxing Li
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD 20850, USA
- Department of Microbiology and Immunology & Center of Biomolecular Therapeutics, University of Maryland School of Medicine, Baltimore, MD 21201, USA
| | - Theodore Jardetzky
- Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Thomas Krey
- Institute of Virology, Hannover Medical School, Hannover 30625, Germany
- German Center for Infection Research (DZIF), 38124 Braunschweig, Germany
- Institute of Biochemistry, Center of Structural and Cell Biology in Medicine, University of Luebeck, D-23538 Luebeck, Germany
- Excellence Cluster 2155 RESIST, Hannover Medical School, 30625 Hannover, Germany
- Centre for Structural Systems Biology (CSSB), 22607 Hamburg, Germany
| | - Bruno E Correia
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne CH-1015, Switzerland.
- Swiss Institute of Bioinformatics (SIB), Lausanne CH-1015, Switzerland
| |
Collapse
|
27
|
Calzas C, Descamps D, Chignard M, Chevalier C. Editorial: Innovative Therapeutic and Vaccine Approaches Against Respiratory Pathogens. Front Immunol 2020; 10:2960. [PMID: 31921201 PMCID: PMC6929520 DOI: 10.3389/fimmu.2019.02960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Accepted: 12/03/2019] [Indexed: 11/18/2022] Open
Affiliation(s)
- Cynthia Calzas
- VIM, INRAE, Université Paris-Saclay, Jouy-en-Josas, France
| | | | - Michel Chignard
- Sorbonne Université, UPMC Univ. Paris 06, INSERM, Centre de Recherche Saint-Antoine, Paris, France
| | | |
Collapse
|
28
|
Bryche B, Frétaud M, Saint-Albin Deliot A, Galloux M, Sedano L, Langevin C, Descamps D, Rameix-Welti MA, Eléouët JF, Le Goffic R, Meunier N. Respiratory syncytial virus tropism for olfactory sensory neurons in mice. J Neurochem 2020; 155:137-153. [PMID: 31811775 DOI: 10.1111/jnc.14936] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 11/29/2019] [Accepted: 12/01/2019] [Indexed: 01/08/2023]
Abstract
The olfactory mucosa, where the first step of odor detection occurs, is a privileged pathway for environmental toxicants and pathogens toward the central nervous system. Indeed, some pathogens can infect olfactory sensory neurons including their axons projecting to the olfactory bulb allowing them to bypass the blood-brain barrier and reach the central nervous system (CNS) through the so-called olfactory pathway. The respiratory syncytial virus (RSV) is a major respiratory tract pathogen but there is growing evidence that RSV may lead to CNS impairments. However, the mechanisms involved in RSV entering into the CNS have been poorly described. In this study, we wanted to explore the capacity of RSV to reach the CNS via the olfactory pathway and to better characterize RSV cellular tropism in the nasal cavity. We first explored the distribution of RSV infectious sites in the nasal cavity by in vivo bioluminescence imaging and a tissue clearing protocol combined with deep-tissue imaging and 3D image analyses. This whole tissue characterization was confirmed with immunohistochemistry and molecular biology approaches. Together, our results provide a novel 3D atlas of mouse nasal cavity anatomy and show that RSV can infect olfactory sensory neurons giving access to the central nervous system by entering the olfactory bulb. Cover Image for this issue: doi: 10.1111/jnc.14765.
Collapse
Affiliation(s)
- Bertrand Bryche
- NBO, INRA, Univ Paris-Saclay, Jouy-en-Josas, France.,Université de Versailles Saint-Quentin en Yvelines, Versailles, France
| | - Maxence Frétaud
- VIM, INRA, Univ Paris Saclay, Jouy-en-Josas, France.,INRA, EMERG'IN- Plateforme d'Infectiologie Expérimentale IERP- Domaine de Vilvert, Jouy-en-Josas, France
| | | | | | - Laura Sedano
- VIM, INRA, Univ Paris Saclay, Jouy-en-Josas, France
| | - Christelle Langevin
- VIM, INRA, Univ Paris Saclay, Jouy-en-Josas, France.,INRA, EMERG'IN- Plateforme d'Infectiologie Expérimentale IERP- Domaine de Vilvert, Jouy-en-Josas, France
| | | | - Marie-Anne Rameix-Welti
- UMR INSERM U1173 I2, UFR des Sciences de la Santé Simone Veil-UVSQ, Montigny-Le-Bretonneux, France.,Assistance Publique-Hôpitaux de Paris, Laboratoire de Microbiologie, Hôpital Ambroise Paré, Boulogne-Billancourt, France
| | | | | | - Nicolas Meunier
- NBO, INRA, Univ Paris-Saclay, Jouy-en-Josas, France.,Université de Versailles Saint-Quentin en Yvelines, Versailles, France
| |
Collapse
|
29
|
San C, Lê MP, Matheron S, Mourvillier B, Caseris M, Timsit JF, Wolff M, Yazdanpanah Y, Descamps D, Peytavin G. Management of oral antiretroviral administration in patients with swallowing disorders or with an enteral feeding tube. Med Mal Infect 2019; 50:537-544. [PMID: 31722864 DOI: 10.1016/j.medmal.2019.10.010] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2018] [Revised: 12/14/2018] [Accepted: 10/18/2019] [Indexed: 02/07/2023]
Abstract
HIV infection has evolved into a chronic disease with comorbidities since the combination antiretroviral therapy era. Complications still occur and patients may need to be admitted to an intensive care unit. Acute respiratory failure is the first cause of these admissions, questioning the administration of solid oral dosage formulations. This issue is also observed in geriatric units where the prevalence of dysphagia is high and underestimated. The problem of antiretroviral administration is critical: altered solid oral dosage formulations and/or administration via enteral feeding tubes are sometimes the only option. The aim is to help manage antiretroviral treatment in unconscious or intubated patients and those with swallowing disorders who are hospitalized in intensive care units or geriatric units. This review provides information on the main antiretroviral regimens and on practical and legal aspects of manipulating solid oral dosage formulations and administration via enteral feeding tubes. Alternatives to the solid formulation are available for most of the 27 oral antiretrovirals available, or manufacturers provide recommendations for patients who are unable to swallow. Manipulation of solid oral dosage formulations such as crushing tablets or opening capsules and administration via feeding tubes are frequently reported but should be the last option for safety and liability issues. Before any off-label administration of a drug, physicians should consider alternatives to the solid oral dosage formulation and check whether the drug can be altered. Therapeutic monitoring is important in this particular setting as the pharmacokinetic profile of drugs is difficult to predict.
Collapse
Affiliation(s)
- Carine San
- Laboratoire de pharmacologie-toxicologie, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - M P Lê
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Laboratoire de pharmacologie-toxicologie, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France.
| | - S Matheron
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - B Mourvillier
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Réanimation médicale et infectieuse, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - M Caseris
- Service de pédiatrie, AP-HP, Hôpital Robert Debré, 75019 Paris, France
| | - J-F Timsit
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Réanimation médicale et infectieuse, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - M Wolff
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Réanimation médicale et infectieuse, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - Y Yazdanpanah
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Service de maladies infectieuses et tropicales, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - D Descamps
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Laboratoire de virologie, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| | - G Peytavin
- Université Paris Diderot Sorbonne Cité, IAME, Inserm UMR 1137, F-75018 Paris, France; Laboratoire de pharmacologie-toxicologie, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France
| |
Collapse
|
30
|
Lambert-Niclot S, Grude M, Chaix ML, Charpentier C, Reigadas S, Le Guillou-Guillemette H, Rodallec A, Amiel C, Maillard A, Dufayard J, Mourez T, Mirand A, Guinard J, Montes B, Vallet S, Marcelin AG, Descamps D, Flandre P, Delaugerre C, Morand-Joubert L. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study). J Antimicrob Chemother 2019; 73:2147-2151. [PMID: 29718247 DOI: 10.1093/jac/dky142] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 03/21/2018] [Indexed: 11/12/2022] Open
Abstract
Background Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on an atazanavir-based regimen. Methods We analysed patients failing on an atazanavir-containing regimen used as a first line of PI therapy. We compared the sequences of reverse transcriptase and protease before the introduction of atazanavir and at failure [two consecutive viral loads (VLs) >50 copies/mL]. Resistance was defined according to the 2014 Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) algorithm. Results Among the 113 patients, atazanavir was used in the first regimen in 71 (62.8%) patients and in the first line of a PI-based regimen in 42 (37.2%). Atazanavir was boosted with ritonavir in 95 (84.1%) patients and combined with tenofovir/emtricitabine or lamivudine (n = 81) and abacavir/lamivudine or emtricitabine (n = 22). At failure, median VL was 3.05 log10 copies/mL and the median CD4+ T cell count was 436 cells/mm3. The median time on atazanavir was 21.2 months. At failure, viruses were considered resistant to atazanavir in four patients (3.5%) with the selection of the following major atazanavir-associated mutations: I50L (n = 1), I84V (n = 2) and N88S (n = 1). Other emergent PI mutations were L10V, G16E, K20I/R, L33F, M36I/L, M46I/L, G48V, F53L, I54L, D60E, I62V, A71T/V, V82I/T, L90M and I93L/M. Emergent NRTI substitutions were detected in 21 patients: M41L (n = 2), D67N (n = 3), K70R (n = 1), L74I/V (n = 3), M184V/I (n = 16), L210W (n = 1), T215Y/F (n = 3) and K219Q/E (n = 2). Conclusions Resistance to atazanavir is rare in patients failing the first line of an atazanavir-based regimen according to the ANRS. Emergent NRTI resistance-associated mutations were reported in 18% of patients.
Collapse
Affiliation(s)
- S Lambert-Niclot
- Sorbonne University, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Service de Virologie, APHP, Hôpital Saint-Antoine, INSERM UPMC UMR_S, Paris, France
| | - M Grude
- INSERM UPMC UMR_S, Paris, France
| | - M L Chaix
- Hôpital Saint-Louis, Université Paris Diderot, INSERM, Paris, France
| | - C Charpentier
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France
| | - S Reigadas
- Hôpital Pellegrin, Centre de ressources biologiques plurithématique, CHU de Bordeaux, Bordeaux, France
| | | | | | - C Amiel
- Hôpital Tenon, UPMC, CR7, Paris, France
| | | | | | - T Mourez
- CHU Charles Nicolle, Rouen, France
| | - A Mirand
- CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - J Guinard
- Hôpital La Source-CHR Orléans, Orléans, France
| | - B Montes
- Hôpital Saint-Eloi, Montpellier, France
| | - S Vallet
- CHRU La Cavale Blanche, Brest, France
| | - A G Marcelin
- Sorbonne University, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Service de Virologie, APHP Hôpital Pitié-Salpêtrière, Paris, France
| | - D Descamps
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France
| | | | - C Delaugerre
- Hôpital Saint-Louis, Université Paris Diderot, INSERM, Paris, France
| | - L Morand-Joubert
- Sorbonne University, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Service de Virologie, APHP, Hôpital Saint-Antoine, INSERM UPMC UMR_S, Paris, France
| | | |
Collapse
|
31
|
Nguyen T, Fofana DB, Lê MP, Charpentier C, Peytavin G, Wirden M, Lambert-Niclot S, Desire N, Grude M, Morand-Joubert L, Flandre P, Katlama C, Descamps D, Calvez V, Todesco E, Marcelin AG. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing. J Antimicrob Chemother 2019; 73:2485-2492. [PMID: 29873733 DOI: 10.1093/jac/dky198] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2018] [Accepted: 04/27/2018] [Indexed: 12/20/2022] Open
Abstract
Background Integrase strand transfer inhibitors (INSTIs) are recommended by international guidelines as first-line therapy in antiretroviral-naive and -experienced HIV-1-infected patients. Objectives This study aimed at evaluating the prevalence at failure of INSTI-resistant variants and the impact of baseline minority resistant variants (MiRVs) on the virological response to an INSTI-based regimen. Methods Samples at failure of 134 patients failing a raltegravir-containing (n = 65), an elvitegravir-containing (n = 20) or a dolutegravir-containing (n = 49) regimen were sequenced by Sanger sequencing and ultra-deep sequencing (UDS). Baseline samples of patients with virological failure (VF) (n = 34) and of those with virological success (VS) (n = 31) under INSTI treatment were sequenced by UDS. Data were analysed using the SmartGene platform, and resistance was interpreted according to the ANRS algorithm version 27. Results At failure, the prevalence of at least one INSTI-resistant variant was 39.6% by Sanger sequencing and 57.5% by UDS, changing the interpretation of resistance in 17/134 (13%) patients. Among 53 patients harbouring at least one resistance mutation detected by both techniques, the most dominant INSTI resistance mutations were N155H (45%), Q148H/K/R (23%), T97A (19%) and Y143C (11%). There was no difference in prevalence of baseline MiRVs between patients with VF and those with VS. MiRVs found at baseline in patients with VF were not detected at failure either in majority or minority mutations. Conclusions UDS is more sensitive than Sanger sequencing at detecting INSTI MiRVs at treatment failure. The presence of MiRVs at failure could be important to the decision to switch to other INSTIs. However, there was no association between the presence of baseline MiRVs and the response to INSTI-based therapies in our study.
Collapse
Affiliation(s)
- T Nguyen
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
| | - D B Fofana
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Saint-Antoine, Laboratoire de virologie, F-75012 Paris, France
| | - M P Lê
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Département de Pharmaco-Toxicologie, Hôpital Bichat-Claude Bernard, Paris, France
| | - C Charpentier
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France
| | - G Peytavin
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Département de Pharmaco-Toxicologie, Hôpital Bichat-Claude Bernard, Paris, France
| | - M Wirden
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
| | - S Lambert-Niclot
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Saint-Antoine, Laboratoire de virologie, F-75012 Paris, France
| | - N Desire
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
| | - M Grude
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), F-75013 Paris, France
| | - L Morand-Joubert
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Saint-Antoine, Laboratoire de virologie, F-75012 Paris, France
| | - P Flandre
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), F-75013 Paris, France
| | - C Katlama
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Service de maladies infectieuses, F-75013 Paris, France
| | - D Descamps
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Paris, France
| | - V Calvez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
| | - E Todesco
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
| | - A G Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de virologie, F-75013 Paris, France
| |
Collapse
|
32
|
Comby A, Descamps D, Beauvarlet S, Gonzalez A, Guichard F, Petit S, Zaouter Y, Mairesse Y. Cascaded harmonic generation from a fiber laser: a milliwatt XUV source. Opt Express 2019; 27:20383-20396. [PMID: 31510133 DOI: 10.1364/oe.27.020383] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
Recent progresses in femtosecond ytterbium-doped fiber laser technology are opening new perspectives in strong field physics and attosecond science. High-order harmonic generation from these systems is particularly interesting because it provides high flux beams of ultrashort extreme ultraviolet radiation. A great deal of effort has been devoted to optimize the macroscopic generation parameters. Here we investigate the possibility of enhancing the single-atom response by producing high-order harmonics from the second, third and fourth harmonics of a turnkey 50 W, 166 kHz femtosecond Yb-fiber laser providing 135 fs pulses at 1030 nm. We show that the harmonic efficiency is optimal when the process is driven by the third harmonic, producing 6.6 ± 1.3 × 1014 photons/s at 18 eV in argon, which corresponds to 1.9 ± 0.4 mW average power.
Collapse
|
33
|
Ferré VM, Ekouevi DK, Gbeasor-Komlanvi FA, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra AC. Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey. Clin Microbiol Infect 2019; 25:1560.e1-1560.e7. [PMID: 31051265 DOI: 10.1016/j.cmi.2019.04.015] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Revised: 04/03/2019] [Accepted: 04/08/2019] [Indexed: 11/24/2022]
Abstract
OBJECTIVES Sub-Saharan Africa is a region with high incidence of both human immunodeficiency virus (HIV) and cervical cancer. We conducted the first national study in Togo to assess prevalence of human papillomavirus (HPV), HIV and other sexually transmitted infections (STIs) among female sex workers (FSW). METHODS A multicentric cross-sectional study was conducted among FSW recruited in hot spots (clubs, streets) in four Togolese cities. HPV and STIs were tested from cervical and anal swabs. HIV and syphilis were screened with rapid tests. RESULTS In all, 310 FSW were recruited; HIV and cervical high-risk HPV (hrHPV) prevalence were 10.6% (33/310) and 32.9% (102/310), respectively. The most frequent hrHPV types were HPV58 (13.6%, 19/140), HPV35 (12.9%, 18/140), HPV31 (12.1%, 17/140) and HPV16 (10.7%, 15/140). Prevalence of hrHPV and multiple hrHPV infections showed higher rates in HIV-positive than in HIV-negative FSW (48.5% versus 31.0%, p 0.04 and 21.2% versus 9.0%, p 0.03; respectively). Prevalence of hrHPV was higher in cervical than anal swabs (34.1% versus 20.7%, p 0.0004). High-risk HPV anal infections were more frequent among HIV-positive than HIV-negative FSW (51.9% versus 17.3%, p 2 × 10-5). Concomitant anal and cervical hrHPV infections were present in 43.2% (41/95) of hrHPV-positive FSW. Overall prevalence in the cervix of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis were 4.2%, 6.1%, 5.5% and 6.5%, respectively. CONCLUSIONS This first African study on paired cervical and anal samples showed a high prevalence of genital HPV infections with a rather high rate of concomitant HPV infections but low type concordance. We report an unusual distribution of hrHPV types. These findings highlight the critical need for implementation of a national HPV vaccination strategy.
Collapse
Affiliation(s)
- V M Ferré
- Université de Paris, IAME, INSERM, F-75018 Paris, France; AP-HP, Hôpital Bichat, DEBRC, F-75018 Paris, France
| | - D K Ekouevi
- Université de Lomé, Faculté des Sciences de la Santé, Département de Santé Publique, Lomé, Togo; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo; ISPED, Université de Bordeaux & Centre INSERM U1219 - Bordeaux Population Health, Bordeaux, France
| | - F A Gbeasor-Komlanvi
- Université de Lomé, Faculté des Sciences de la Santé, Département de Santé Publique, Lomé, Togo; Centre Africain de Recherche en Epidémiologie et en Santé Publique (CARESP), Lomé, Togo
| | - G Collin
- Université de Paris, IAME, INSERM, F-75018 Paris, France; AP-HP, Hôpital Bichat, DEBRC, F-75018 Paris, France
| | - Q Le Hingrat
- Université de Paris, IAME, INSERM, F-75018 Paris, France; AP-HP, Hôpital Bichat, DEBRC, F-75018 Paris, France
| | - B Tchounga
- Programme PACCI, site ANRS, Abidjan, Cote d'Ivoire
| | - M Salou
- Université de Lomé, Centre de Biologie Moléculaire et d'Immunologie, Lomé, Togo
| | - D Descamps
- Université de Paris, IAME, INSERM, F-75018 Paris, France; AP-HP, Hôpital Bichat, DEBRC, F-75018 Paris, France
| | - C Charpentier
- Université de Paris, IAME, INSERM, F-75018 Paris, France; AP-HP, Hôpital Bichat, DEBRC, F-75018 Paris, France.
| | - A C Dagnra
- Université de Lomé, Centre de Biologie Moléculaire et d'Immunologie, Lomé, Togo; Programme national de lutte contre le sida et les infections sexuellement transmissibles, Lomé, Togo
| |
Collapse
|
34
|
Quintard L, Strelkov V, Vabek J, Hort O, Dubrouil A, Descamps D, Burgy F, Péjot C, Mével E, Catoire F, Constant E. Optics-less focusing of XUV high-order harmonics. Sci Adv 2019; 5:eaau7175. [PMID: 30972360 PMCID: PMC6450687 DOI: 10.1126/sciadv.aau7175] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2018] [Accepted: 02/12/2019] [Indexed: 05/23/2023]
Abstract
By experimentally studying high-order harmonic beams generated in gases, we show how the spatial characteristics of these ultrashort extreme-ultraviolet (XUV) beams can be finely controlled when a single fundamental beam generates harmonics in a thin gas medium. We demonstrate that these XUV beams can be emitted as converging beams and thereby get focused after generation. We study this optics-less focusing using a spatially chirped beam that acts as a probe located inside the harmonic generation medium. We analyze the XUV beam evolution with an analytical model and obtain very good agreement with experimental measurements. The XUV foci sizes and positions vary strongly with the harmonic order, and the XUV waist can be located at arbitrarily large distances from the generating medium. We discuss how intense XUV fields can be obtained with optics-less focusing and how the order-dependent XUV beam characteristics are compatible with broadband XUV irradiation and attosecond science.
Collapse
Affiliation(s)
- L. Quintard
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - V. Strelkov
- Prokhorov General Physics Institute of the Russian Academy of Sciences, 38, Vavilova Street, Moscow 119991, Russia
- Moscow Institute of Physics and Technology (State University), 141700 Dolgoprudny, Moscow Region, Russia
| | - J. Vabek
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - O. Hort
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - A. Dubrouil
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - D. Descamps
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - F. Burgy
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - C. Péjot
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - E. Mével
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - F. Catoire
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
| | - E. Constant
- Université de Bordeaux, CNRS, CEA, Centre Laser Intenses et Applications (CELIA), 43 rue P. Noailles, 33400 Talence, France
- Université de Lyon, Université Claude Bernard Lyon 1, CNRS, Institut Lumière Matière (ILM), 69622 Villeurbanne, France
| |
Collapse
|
35
|
Nguyen A, Kaltenecker KJ, Delagnes JC, Zhou B, Cormier E, Fedorov N, Bouillaud R, Descamps D, Thiele I, Skupin S, Jepsen PU, Bergé L. Wavelength scaling of terahertz pulse energies delivered by two-color air plasmas. Opt Lett 2019; 44:1488-1491. [PMID: 30874683 DOI: 10.1364/ol.44.001488] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2018] [Accepted: 02/07/2019] [Indexed: 06/09/2023]
Abstract
We address the long-standing problem of anomalous growth observed in the terahertz (THz) energy yield from air plasmas created by two-color laser pulses, as the fundamental wavelength λ0 is increased. Using two distinct optical parametric amplifiers (OPAs), we report THz energies scaling like λ0α with large exponents 5.6≤α≤14.3, which departs from the growth in λ02 expected from photocurrent theory. By means of comprehensive 3D simulations, we demonstrate that the changes in the laser beam size, pulse duration, and phase-matching conditions in the second-harmonic generation process when tuning the OPA's carrier wavelength can lead to these high scaling powers. The value of the phase angle between the two colors reached at the exit of the doubling crystal turns out to be crucial and even explains non-monotonic behaviors in the measurements.
Collapse
|
36
|
Sesterhenn F, Galloux M, Vollers SS, Csepregi L, Yang C, Descamps D, Bonet J, Friedensohn S, Gainza P, Corthésy P, Chen M, Rosset S, Rameix-Welti MA, Éléouët JF, Reddy ST, Graham BS, Riffault S, Correia BE. Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen. PLoS Biol 2019; 17:e3000164. [PMID: 30789898 PMCID: PMC6400402 DOI: 10.1371/journal.pbio.3000164] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 03/05/2019] [Accepted: 02/08/2019] [Indexed: 12/20/2022] Open
Abstract
Throughout the last several decades, vaccination has been key to prevent and eradicate infectious diseases. However, many pathogens (e.g., respiratory syncytial virus [RSV], influenza, dengue, and others) have resisted vaccine development efforts, largely because of the failure to induce potent antibody responses targeting conserved epitopes. Deep profiling of human B cells often reveals potent neutralizing antibodies that emerge from natural infection, but these specificities are generally subdominant (i.e., are present in low titers). A major challenge for next-generation vaccines is to overcome established immunodominance hierarchies and focus antibody responses on crucial neutralization epitopes. Here, we show that a computationally designed epitope-focused immunogen presenting a single RSV neutralization epitope elicits superior epitope-specific responses compared to the viral fusion protein. In addition, the epitope-focused immunogen efficiently boosts antibodies targeting the palivizumab epitope, resulting in enhanced neutralization. Overall, we show that epitope-focused immunogens can boost subdominant neutralizing antibody responses in vivo and reshape established antibody hierarchies. A computationally designed epitope-focused immunogen presenting a single neutralization epitope from Respiratory Syncytial Virus elicits superior epitope-specific responses compared to the viral fusion protein. Furthermore, epitope-focused immunogens can reshape established antibody hierarchies. Vaccines are one of the most valuable instruments to prevent and control infectious diseases. Their primary correlate of protection is the level of induction of neutralizing antibodies that target critical antigenic sites and thereby block infection. Natural infections with pathogens such as the respiratory syncytial virus (RSV) or influenza induce a broad repertoire of antibodies that target multiple epitopes. Among those, functional antibodies with key specificities are often subdominant (present in low titers). Thus, a central goal for vaccine development is to focus antibody responses on such neutralization epitopes. Here, we show that a computationally designed, epitope-focused immunogen mimicking an important RSV neutralization epitope (site II) can focus antibodies onto this well-defined epitope. In a scenario of preexisting immunity, in which site II–specific antibodies were subdominant, the epitope-focused immunogen selectively boosted site II–specific antibodies, resulting in an increased viral neutralization through this epitope. We propose that rationally designed immunogens spotlighting defined epitopes have a unique potential to focus antibody responses on functionally conserved sites in cases of preexisting immunity. Our results have broad implications for vaccine design as a strategy to steer preexisting antibody responses away from immunodominant, variable epitopes and toward subdominant epitopes that confer broad and potent neutralization.
Collapse
MESH Headings
- Animals
- Antibodies, Monoclonal, Humanized/chemistry
- Antibodies, Monoclonal, Humanized/immunology
- Antibodies, Neutralizing/biosynthesis
- Antibodies, Neutralizing/genetics
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/genetics
- Cloning, Molecular
- Computer-Aided Design
- Epitopes/chemistry
- Epitopes/immunology
- Escherichia coli/genetics
- Escherichia coli/metabolism
- Female
- Gene Expression
- Genetic Vectors/chemistry
- Genetic Vectors/metabolism
- Immunization/methods
- Immunogenicity, Vaccine
- Mice
- Mice, Inbred BALB C
- Nanoparticles/administration & dosage
- Nanoparticles/chemistry
- Palivizumab/chemistry
- Palivizumab/immunology
- Receptors, Antigen, B-Cell/chemistry
- Receptors, Antigen, B-Cell/genetics
- Receptors, Antigen, B-Cell/immunology
- Recombinant Fusion Proteins/administration & dosage
- Recombinant Fusion Proteins/chemistry
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Respiratory Syncytial Virus Vaccines/administration & dosage
- Respiratory Syncytial Virus Vaccines/biosynthesis
- Respiratory Syncytial Virus Vaccines/genetics
- Respiratory Syncytial Viruses/immunology
- Structural Homology, Protein
- Viral Fusion Proteins/administration & dosage
- Viral Fusion Proteins/chemistry
- Viral Fusion Proteins/genetics
- Viral Fusion Proteins/immunology
Collapse
Affiliation(s)
- Fabian Sesterhenn
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - Marie Galloux
- Unité de Virologie et Immunologie Moléculaires (UR892), INRA, Université Paris-Saclay, Jouy-en-Josas, France
| | - Sabrina S. Vollers
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Lucia Csepregi
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
| | - Che Yang
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - Delphyne Descamps
- Unité de Virologie et Immunologie Moléculaires (UR892), INRA, Université Paris-Saclay, Jouy-en-Josas, France
| | - Jaume Bonet
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - Simon Friedensohn
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
| | - Pablo Gainza
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
| | - Patricia Corthésy
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Man Chen
- Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Stéphane Rosset
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Marie-Anne Rameix-Welti
- UMR1173, INSERM, Université de Versailles St. Quentin, Montigny le Bretonneux, France
- AP-HP, Laboratoire de Microbiologie, Hôpital Ambroise Paré, Boulogne-Billancourt, France
| | - Jean-François Éléouët
- Unité de Virologie et Immunologie Moléculaires (UR892), INRA, Université Paris-Saclay, Jouy-en-Josas, France
| | - Sai T. Reddy
- Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
| | - Barney S. Graham
- Viral Pathogenesis Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
| | - Sabine Riffault
- Unité de Virologie et Immunologie Moléculaires (UR892), INRA, Université Paris-Saclay, Jouy-en-Josas, France
| | - Bruno E. Correia
- Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
- Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland
- * E-mail:
| |
Collapse
|
37
|
Comby A, Bloch E, Bond CMM, Descamps D, Miles J, Petit S, Rozen S, Greenwood JB, Blanchet V, Mairesse Y. Real-time determination of enantiomeric and isomeric content using photoelectron elliptical dichroism. Nat Commun 2018; 9:5212. [PMID: 30523259 PMCID: PMC6283843 DOI: 10.1038/s41467-018-07609-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 11/09/2018] [Indexed: 11/09/2022] Open
Abstract
The fast and accurate analysis of chiral chemical mixtures is crucial for many applications but remains challenging. Here we use elliptically-polarized femtosecond laser pulses at high repetition rates to photoionize chiral molecules. The 3D photoelectron angular distribution produced provides molecular fingerprints, showing a strong forward-backward asymmetry which depends sensitively on the molecular structure and degree of ellipticity. Continuously scanning the laser ellipticity and analyzing the evolution of the rich, multi-dimensional molecular signatures allows us to observe real-time changes in the chemical and chiral content present with unprecedented speed and accuracy. We measure the enantiomeric excess of a compound with an accuracy of 0.4% in 10 min acquisition time, and follow the evolution of a mixture with an accuracy of 5% with a temporal resolution of 3 s. This method is even able to distinguish isomers, which cannot be easily distinguished by mass-spectrometry.
Collapse
Affiliation(s)
- A Comby
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F33405, Talence, France
| | - E Bloch
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F33405, Talence, France
| | - C M M Bond
- School of Maths and Physics, Queen's University, Belfast, BT7 INN, UK
| | - D Descamps
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F33405, Talence, France
| | - J Miles
- School of Maths and Physics, Queen's University, Belfast, BT7 INN, UK
| | - S Petit
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F33405, Talence, France
| | - S Rozen
- Weizmann Institute of Science, Rehovot, 76100, Israel
| | - J B Greenwood
- School of Maths and Physics, Queen's University, Belfast, BT7 INN, UK
| | - V Blanchet
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F33405, Talence, France
| | - Y Mairesse
- Université de Bordeaux - CNRS - CEA, CELIA, UMR5107, F33405, Talence, France.
| |
Collapse
|
38
|
Beaulieu S, Comby A, Descamps D, Petit S, Légaré F, Fabre B, Blanchet V, Mairesse Y. Multiphoton photoelectron circular dichroism of limonene with independent polarization state control of the bound-bound and bound-continuum transitions. J Chem Phys 2018; 149:134301. [DOI: 10.1063/1.5042533] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- S. Beaulieu
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
- Institut National de la Recherche Scientifique, Centre EMT, Varennes, Quebec J3X 1S2,
Canada
| | - A. Comby
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
| | - D. Descamps
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
| | - S. Petit
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
| | - F. Légaré
- Institut National de la Recherche Scientifique, Centre EMT, Varennes, Quebec J3X 1S2,
Canada
| | - B. Fabre
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
| | - V. Blanchet
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
| | - Y. Mairesse
- Université de Bordeaux—CNRS—CEA, CELIA, UMR5107, F33405 Talence, France
| |
Collapse
|
39
|
Mathieu E, Escribano-Vazquez U, Descamps D, Cherbuy C, Langella P, Riffault S, Remot A, Thomas M. Paradigms of Lung Microbiota Functions in Health and Disease, Particularly, in Asthma. Front Physiol 2018; 9:1168. [PMID: 30246806 PMCID: PMC6110890 DOI: 10.3389/fphys.2018.01168] [Citation(s) in RCA: 122] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 08/03/2018] [Indexed: 12/22/2022] Open
Abstract
Improvements in our knowledge of the gut microbiota have broadened our vision of the microbes associated with the intestine. These microbes are essential actors and protectors of digestive and extra-digestive health and, by extension, crucial for human physiology. Similar reconsiderations are currently underway concerning the endogenous microbes of the lungs, with a shift in focus away from their involvement in infections toward a role in physiology. The discovery of the lung microbiota was delayed by the long-held view that the lungs of healthy individuals were sterile and by sampling difficulties. The lung microbiota has a low density, and the maintenance of small numbers of bacteria seems to be a critical determinant of good health. This review aims to highlight how knowledge about the lung microbiota can change our conception of lung physiology and respiratory health. We provide support for this point of view with knowledge acquired about the gut microbiota and intestinal physiology. We describe the main characteristics of the lung microbiota and its functional impact on lung physiology, particularly in healthy individuals, after birth, but also in asthma. We describe some of the physiological features of the respiratory tract potentially favoring the installation of a dysbiotic microbiota. The gut microbiota feeds and matures the intestinal epithelium and is involved in immunity, when the principal role of the lung microbiota seems to be the orientation and balance of aspects of immune and epithelial responsiveness. This implies that the local and remote effects of bacterial communities are likely to be determinant in many respiratory diseases caused by viruses, allergens or genetic deficiency. Finally, we discuss the reciprocal connections between the gut and lungs that render these two compartments inseparable.
Collapse
Affiliation(s)
- Elliot Mathieu
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Unai Escribano-Vazquez
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Delphyne Descamps
- Virologie et Immunologie Moléculaires, Institut National de la Recherche Agronomique, Université Paris-Saclay, Jouy-en-Josas, France
| | - Claire Cherbuy
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Philippe Langella
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Sabine Riffault
- Virologie et Immunologie Moléculaires, Institut National de la Recherche Agronomique, Université Paris-Saclay, Jouy-en-Josas, France
| | - Aude Remot
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| | - Muriel Thomas
- Micalis Institute, Institut National de la Recherche Agronomique, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France
| |
Collapse
|
40
|
Gallien S, Massetti M, Flandre P, Leleu H, Descamps D, Lazaro E. Comparison of 48-week efficacies of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimens: a systematic review and network meta-analysis. HIV Med 2018; 19:559-571. [PMID: 30004176 DOI: 10.1111/hiv.12643] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/17/2018] [Indexed: 02/01/2023]
Abstract
OBJECTIVES To compare nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)-sparing regimens with tenofovir alafenamide (TAF)-based combinations in HIV-1-infected adults, we performed a network meta-analysis (NMA) to provide estimates of relative efficacy for these two regimens. METHODS A systematic literature review (SLR) was performed to identify phase 3/4 randomized controlled clinical trials evaluating the efficacy of commonly used combination antiretroviral therapy (cART) including an NRTI backbone or that of commonly used NRTI-sparing regimens. A Bayesian random-effect model was used to compare virological suppression rates at 48 weeks for NRTI-sparing regimens and elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF). RESULTS Twenty-three studies in treatment-naïve patients identified by the SLR were included in the NMA, including four studies assessing NRTI-sparing regimens. In treatment-naïve patients, the probability of achieving virological suppression at 48 weeks was between 40% and 60% higher with E/C/F/TAF than with NRTI-sparing strategies. The credible interval vs. darunavir/ritonavir (DVR/r) + raltegravir (RAL) and LPV/r monotherapy did not include 1. In the subgroup of naïve patients with viral load < 100 000 HIV-1 RNA copies/mL, a credible difference was found between NRTI-sparing treatments and E/C/F/TAF. Studies in treatment-experienced patients were too heterogeneous to allow for an NMA. CONCLUSIONS The NMA results suggest that E/C/F/TAF represents a more effective option than NRTI-sparing regimens in terms of 48-week efficacy in treatment-naïve patients. Furthermore, TAF pharmacological properties, as well as tolerability results in clinical studies, suggest a safety profile similar to that of NRTI-sparing regimens. Thus, the E/C/F/TAF combination might represent a more appropriate option than NRTI-sparing regimens for initiation of antiretroviral therapy in treatment-naïve HIV-infected patients.
Collapse
Affiliation(s)
- S Gallien
- Henri Mondor University Hospital, Créteil, France
- University of Paris-Est Créteil Val de Marne Medical School, Créteil, France
| | | | - P Flandre
- INSERM Sorbonne University, UPMC University Paris 06, UMR-S 1136, Pierre Louis Institute of Epidemiology and Public Health, Paris, France
| | - H Leleu
- Public Health Expertise, Paris, France
| | - D Descamps
- Bichat Claude Bernard University Hospital, Paris, France
- University Paris Diderot Medical School, Paris, France
| | - E Lazaro
- Bordeaux University Hospital, Bordeaux, France
- University of Bordeaux, Bordeaux, France
| |
Collapse
|
41
|
Nguyen S, Baillie C, Hilmoine A, Oddoux O, Anastay M, Descamps D. Analyse des bactériémies chez les patients cirrhotiques dans un centre hospitalier général. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Nguyen S, Baillie C, Hilmoine A, Oddoux O, Anastay M, Descamps D. Analyse des bactériémies chez les patients diabétiques dans un centre hospitalier général. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
43
|
Brunet-Possenti F, Charpentier C, Collin G, Descamps D, Descamps V. Impact of anti-interleukin-17 treatment on cutaneous and genital human papillomavirus infection. Br J Dermatol 2018; 179:1179-1180. [PMID: 29777619 DOI: 10.1111/bjd.16799] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- F Brunet-Possenti
- Department of Dermatology, Bichat Claude Bernard Hospital, AP-HP, Paris, France.,IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France
| | - C Charpentier
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France
| | - G Collin
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France
| | - D Descamps
- IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France
| | - V Descamps
- Department of Dermatology, Bichat Claude Bernard Hospital, AP-HP, Paris, France
| |
Collapse
|
44
|
Alessandri-Gradt E, Collin G, Tourneroche A, Bertine M, Leoz M, Charpentier C, Unal G, Descamps D, Plantier JC. HIV-1 non-group M phenotypic susceptibility to integrase strand transfer inhibitors. J Antimicrob Chemother 2018; 72:2431-2437. [PMID: 28859447 DOI: 10.1093/jac/dkx190] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2017] [Accepted: 05/23/2017] [Indexed: 11/13/2022] Open
Abstract
Objectives To determine natural phenotypic susceptibility of non-group M HIV-1 to integrase strand transfer inhibitors (INSTIs) in a large panel of 39 clinical strains from groups O, N and P and to identify genotypic polymorphisms according to susceptibility levels. Methods Susceptibility to raltegravir, elvitegravir and dolutegravir was evaluated in 36 HIV-1/O, 2 HIV-1/N and 1 HIV-1/P strains plus an HIV-1/M reference strain. IC50 values were determined after 3 days, and fold changes (FCs) were calculated relative to the HIV-1/M strain. Genotypic polymorphism was determined by amplification of codons 19-263 of the integrase; the natural occurrence of resistance-associated mutations was analysed using the main resistance algorithms and the IAS-USA list. VESPA analysis of the strain sequences was used to determine a signature pattern associated with higher FC. Results Similar IC50 results were observed for the three drugs. Based on the value for the HIV-1/M reference strain, the data showed FC values <2.5 for raltegravir and dolutegravir, whereas the distribution for elvitegravir was heterogeneous, with FC > 10 for six strains (15%). Analysis of the non-M integrase sequences showed a high level of polymorphism without a major genotypic impact; it also revealed mutations that may be associated with the highest FC values obtained for elvitegravir. Conclusions Our phenotypic data showed that non-M strains are globally susceptible to the three currently used INSTIs, but the impact of the high FC values observed for some strains with elvitegravir needs to be explored. Clinical data are now needed to confirm these phenotypic results.
Collapse
Affiliation(s)
- E Alessandri-Gradt
- Normandie Univ., UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, F-76000 Rouen, France
| | - G Collin
- IAME, UMR 1137, Univ. Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France.,IAME, UMR 1137, INSERM, F-75018 Paris, France.,AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018 Paris, France
| | - A Tourneroche
- Normandie Univ., UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, F-76000 Rouen, France
| | - M Bertine
- IAME, UMR 1137, Univ. Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France.,IAME, UMR 1137, INSERM, F-75018 Paris, France.,AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018 Paris, France
| | - M Leoz
- Normandie Univ., UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, F-76000 Rouen, France
| | - C Charpentier
- IAME, UMR 1137, Univ. Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France.,IAME, UMR 1137, INSERM, F-75018 Paris, France.,AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018 Paris, France
| | - G Unal
- Normandie Univ., UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, F-76000 Rouen, France
| | - D Descamps
- IAME, UMR 1137, Univ. Paris Diderot, Sorbonne Paris Cité, F-75018 Paris, France.,IAME, UMR 1137, INSERM, F-75018 Paris, France.,AP-HP, Hôpital Bichat-Claude Bernard, Laboratoire de Virologie, F-75018 Paris, France
| | - J C Plantier
- Normandie Univ., UNIROUEN, EA2656, GRAM, CHU de Rouen, Laboratoire de Virologie associé au CNR du VIH, F-76000 Rouen, France
| |
Collapse
|
45
|
Visseaux B, Bertine M, Storto A, Damond F, Collin F, Chêne G, Matheron S, Charpentier C, Hué S, Descamps D. A28 Phylogeographic analysis of HIV-2 ANRS CO5 cohort reveals new trends in HIV-2 epidemic patterns in West Africa. Virus Evol 2018. [PMCID: PMC5905445 DOI: 10.1093/ve/vey010.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- B Visseaux
- IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France
| | - M Bertine
- IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France
| | - A Storto
- IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France
| | - F Damond
- IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France
| | - F Collin
- Université Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
| | - G Chêne
- Université Bordeaux, ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux, France
| | - S Matheron
- IAME, UMR 1137, INSERM, Maladies Infectieuses et Tropicales, Univ Paris Diderot, Hôpital Bichat, Sorbonne Paris Cité, AP-HP, Paris, France
| | - C Charpentier
- IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France
| | - S Hué
- LSHTM, London, UK and Hopital Bichat-Claude Bernard, AP-HP, Paris, France
| | - D Descamps
- IAME, UMR 1137, Univ Paris Diderot, Sorbonne Paris Cité, INSERM; AP-HP, Hôpital Bichat, Virologie, Paris, France
| | | |
Collapse
|
46
|
Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. Corrigendum to "HIV-2 molecular epidemiology" [Infect. Genet. Evol. 46 (2016) 233-240]. Infect Genet Evol 2018; 58:294. [PMID: 29307762 DOI: 10.1016/j.meegid.2017.12.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Affiliation(s)
- B Visseaux
- INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, F-75018 Paris, France.
| | - F Damond
- INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, F-75018 Paris, France
| | - S Matheron
- INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Service de Maladies Infectieuses et Tropicales, F-75018 Paris, France
| | - D Descamps
- INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, F-75018 Paris, France
| | - C Charpentier
- INSERM, IAME, UMR 1137, F-75018 Paris, France; Université Paris Diderot, IAME, UMR 1137, Sorbonne Paris Cité, F-75018 Paris, France; AP-HP, Hôpital Bichat, Laboratoire de Virologie, F-75018 Paris, France
| |
Collapse
|
47
|
Beaulieu S, Comby A, Clergerie A, Caillat J, Descamps D, Dudovich N, Fabre B, Géneaux R, Légaré F, Petit S, Pons B, Porat G, Ruchon T, Taïeb R, Blanchet V, Mairesse Y. Attosecond-resolved photoionization of chiral molecules. Science 2017; 358:1288-1294. [DOI: 10.1126/science.aao5624] [Citation(s) in RCA: 116] [Impact Index Per Article: 16.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2017] [Accepted: 11/10/2017] [Indexed: 11/02/2022]
|
48
|
Bouscarat F, Tantet C, Lariven S, Descamps V, Descamps D, Yazdanpanah Y, Charpentier C. Détection et génotypage « multisite » des Papillomavirus Beta au cours d’un cas d’épidermodysplasie verruciforme (EV) associée à l’infection VIH. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
49
|
Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study. J Antimicrob Chemother 2017; 72:1769-1773. [PMID: 28333232 DOI: 10.1093/jac/dkx042] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2016] [Accepted: 01/19/2017] [Indexed: 11/14/2022] Open
Abstract
Background Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance. Methods The HIV-1 protease and reverse transcriptase (RT) and integrase genes were sequenced in plasma samples from 782 consecutive patients on failing antiretroviral regimens, seen in 37 specialized centres in 2014. The genotyping results were interpreted using the ANRS v24 algorithm. Prevalence rates were compared with those obtained during a similar survey conducted in 2009. Results The protease and RT sequences were obtained in 566 patients, and the integrase sequence in 382 patients. Sequencing was successful in 60%, 78%, 78% and 87% of patients with VLs of 51-200, 201-500, 501-1000 and >1000 copies/mL, respectively. Resistance to at least one antiretroviral drug was detected in 56.3% of samples. Respectively, 3.9%, 8.7%, 1.5% and 3.4% of patients harboured viruses that were resistant to any NRTI, NNRTI, PI and integrase inhibitor (INI). Resistance rates were lower in 2014 than in 2009. Resistance was detected in 48.5% of samples from patients with a VL between 51 and 200 copies/mL. Conclusion In France in 2014, 90.0% of patients in AIDS care centres were receiving antiretroviral drugs and 12.0% of them had VLs >50 copies/mL. Therefore, this study suggests that 6.7% of treated patients in France might transmit resistant strains. Resistance testing may be warranted in all treated patients with VL > 50 copies/mL.
Collapse
Affiliation(s)
- L Assoumou
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013 Paris, France
| | - C Charpentier
- INSERM UMR1137, IAME Université Paris Diderot Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Laboratoire Associé au Centre National de Référence du VIH-Résistance aux Antirétroviraux, Paris, France
| | - P Recordon-Pinson
- PTBM, Laboratoire de Virologie, Hôpital Pellegrin, CHU de Bordeaux; UMR 5234 MFP CNRS, Université de Bordeaux, 33076 Bordeaux cedex, France
| | - M Grudé
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013 Paris, France
| | - C Pallier
- HU Paris sud, Hôpital Paul Brousse, Laboratoire de Virologie, Villejuif, France
| | - L Morand-Joubert
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Laboratoire de Virologie, Hôpital Saint-Antoine, F75012 Paris, France
| | - S Fafi-Kremer
- Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - A Krivine
- AP-HP, Hôpital Cochin, Laboratoire de Virologie, Paris, France
| | - B Montes
- Laboratoire de Virologie, Hôpital Saint-Eloi, CHU Montpellier, Montpellier, France
| | - V Ferré
- EA 4271, Nantes Université UFR Pharmacie, Laboratoire de Virologie, CHU Nantes, Nantes, France
| | - M Bouvier-Alias
- INSERM U955, National Reference Center for Viral Hepatitis B, C et Delta, Department of Virology, Henri Mondor Hospital, University of Paris-Est, Créteil, France
| | - J-C Plantier
- Laboratoire de Virologie et COREVIH Haute-Normandie, CHU de Rouen, Rouen, France
| | - J Izopet
- Laboratoire de Virologie, Hôpital Purpan de Toulouse, Toulouse, France
| | - M-A Trabaud
- Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
| | - S Yerly
- Laboratoire de Virologie, Hôpitaux Universitaires de Genève, Genève, Switzerland
| | - J Dufayard
- Laboratoire de Virologie, Hôpital l'Archet de Nice, Nice, France
| | - C Alloui
- Laboratoire de Virologie, Hôpital Avicenne, APHP, HU Paris Seine Saint Denis, Bobigny, France
| | - L Courdavault
- Laboratoire de Virologie, Centre Hospitalier Victor Dupouy d'Argenteuil, Argenteuil, France
| | - H Le Guillou-Guillemette
- Laboratoire de Virologie, CHU Angers et HIFIH Laboratory, UPRES 3859, SFR 4208, LUNAM University, Angers, France
| | - A Maillard
- Laboratoire de Virologie, CHU de Rennes, Rennes, France
| | - C Amiel
- AP-HP, Hôpital Tenon, Laboratoire de Virologie, Paris, France
| | - A Vabret
- Laboratoire de Virologie, CHU Caen, Caen, France
| | - C Roussel
- Laboratoire de Virologie, CHU Amiens, Amiens, France
| | - S Vallet
- Laboratoire de Virologie, CHU Brest, Brest, France
| | - J Guinard
- Laboratoire de Virologie, CHR Orléans, Orléans, France
| | - A Mirand
- Laboratoire de Virologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - A Beby-Defaux
- Laboratoire de Virologie, CHU Poitiers, Poitiers, France
| | - F Barin
- Laboratoire de Virologie, CHU Bretonneau, & INSERM U966, Tours, France
| | | | - R Ait-Namane
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique (IPLESP UMRS 1136), F75013 Paris, France
| | - M Wirden
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Laboratoire de Virologie, Hôpital Pitié-Salpêtrière, F75013 Paris, France
| | - C Delaugerre
- Laboratoire de Virologie, AP-HP, Hôpital Saint Louis, INSERM U941, Université Paris Diderot, Paris, France
| | - V Calvez
- Sorbonne Universités, UPMC Univ. Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), AP-HP, Laboratoire de Virologie, Hôpital Pitié-Salpêtrière, F75013 Paris, France
| | - M-L Chaix
- Laboratoire de Virologie, AP-HP, Hôpital Saint Louis, INSERM U941, Université Paris Diderot, Paris, France
| | - D Descamps
- INSERM UMR1137, IAME Université Paris Diderot Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat-Claude Bernard, Laboratoire Associé au Centre National de Référence du VIH-Résistance aux Antirétroviraux, Paris, France
| | - S Reigadas
- PTBM, Laboratoire de Virologie, Hôpital Pellegrin, CHU de Bordeaux; UMR 5234 MFP CNRS, Université de Bordeaux, 33076 Bordeaux cedex, France.,CRB plurithématique, Bordeaux Biothèques Santé, Groupe hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France
| | | |
Collapse
|
50
|
Zhivaki D, Lemoine S, Lim A, Morva A, Vidalain PO, Schandene L, Casartelli N, Rameix-Welti MA, Hervé PL, Dériaud E, Beitz B, Ripaux-Lefevre M, Miatello J, Lemercier B, Lorin V, Descamps D, Fix J, Eléouët JF, Riffault S, Schwartz O, Porcheray F, Mascart F, Mouquet H, Zhang X, Tissières P, Lo-Man R. Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity. Immunity 2017; 46:301-314. [PMID: 28228284 PMCID: PMC7128247 DOI: 10.1016/j.immuni.2017.01.010] [Citation(s) in RCA: 88] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Revised: 11/09/2016] [Accepted: 12/20/2016] [Indexed: 12/22/2022]
Abstract
Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infections in infants and is characterized by pulmonary infiltration of B cells in fatal cases. We analyzed the B cell compartment in human newborns and identified a population of neonatal regulatory B lymphocytes (nBreg cells) that produced interleukin 10 (IL-10) in response to RSV infection. The polyreactive B cell receptor of nBreg cells interacted with RSV protein F and induced upregulation of chemokine receptor CX3CR1. CX3CR1 interacted with RSV glycoprotein G, leading to nBreg cell infection and IL-10 production that dampened T helper 1 (Th1) cytokine production. In the respiratory tract of neonates with severe RSV-induced acute bronchiolitis, RSV-infected nBreg cell frequencies correlated with increased viral load and decreased blood memory Th1 cell frequencies. Thus, the frequency of nBreg cells is predictive of the severity of acute bronchiolitis disease and nBreg cell activity may constitute an early-life host response that favors microbial pathogenesis. Identified a neonatal-specific subset of regulatory B (nBreg) cells in the blood Neonatal nBreg cells are infected by RSV via the BCR and CX3CR1 RSV-infected nBreg cells produce anti-inflammatory IL-10 that dowregulates Th1 cell responses Blood nBreg cells are a biomarker of lung disease severity in RSV+ patients
Collapse
Affiliation(s)
- Dania Zhivaki
- Neonatal Immunity Group, Human Histopathology and Animal Models, Institut Pasteur, Paris 75724, France; Paris 7 Diderot University, Paris 75724, France
| | - Sébastien Lemoine
- Régulation Immunitaire et Vaccinologie, Institut Pasteur, Paris 75724, France; INSERM U1041, Paris 75724, France
| | - Annick Lim
- Departement d'Immunologie, Institut Pasteur, Paris 75724, France
| | - Ahsen Morva
- Neonatal Immunity Group, Human Histopathology and Animal Models, Institut Pasteur, Paris 75724, France
| | | | | | - Nicoletta Casartelli
- Virus et Immunité, Institut Pasteur, Paris 75724, France; UMR CNRS 3568, Paris 75724, France
| | - Marie-Anne Rameix-Welti
- INSERM U1173, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines 78180, France; AP-HP, Laboratoire de Microbiologie, Hôpital Ambroise Paré, Boulogne-Billancourt 92100, France
| | - Pierre-Louis Hervé
- Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, Jouy-en-Josas 78350, France
| | - Edith Dériaud
- Régulation Immunitaire et Vaccinologie, Institut Pasteur, Paris 75724, France; INSERM U1041, Paris 75724, France
| | - Benoit Beitz
- Bioaster Microbiology Technology Institute, Paris 75015, France
| | | | - Jordi Miatello
- APHP, Pediatric ICU and Neonatal Medicine, Paris South University Hospitals, Le Kremlin-Bicetre 94270, France; School of Medicine, Paris South University, Le Kremlin-Bicêtre 94270, France; Institute of Integrative Biology of the Cell - UMR 9196, Paris Saclay University, Gif-sur-Yvette 91190, France
| | | | - Valerie Lorin
- Laboratory of Humoral Response to Pathogens, Department of Immunology, Institut Pasteur, Paris 75724, France; INSERM U1222, Paris 75724, France
| | - Delphyne Descamps
- Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, Jouy-en-Josas 78350, France
| | - Jenna Fix
- Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, Jouy-en-Josas 78350, France
| | - Jean-François Eléouët
- Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, Jouy-en-Josas 78350, France
| | - Sabine Riffault
- Unité de Virologie et Immunologie Moléculaires, INRA, Université Paris-Saclay, Jouy-en-Josas 78350, France
| | - Olivier Schwartz
- Virus et Immunité, Institut Pasteur, Paris 75724, France; UMR CNRS 3568, Paris 75724, France
| | | | - Françoise Mascart
- Immunobiology Clinic, Hopital Erasme, Brussels 1070, Belgium; Laboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles, Brussels 1070, Belgium
| | - Hugo Mouquet
- Laboratory of Humoral Response to Pathogens, Department of Immunology, Institut Pasteur, Paris 75724, France; INSERM U1222, Paris 75724, France
| | - Xiaoming Zhang
- Unit of Innate Defense and Immune Modulation, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China
| | - Pierre Tissières
- APHP, Pediatric ICU and Neonatal Medicine, Paris South University Hospitals, Le Kremlin-Bicetre 94270, France; School of Medicine, Paris South University, Le Kremlin-Bicêtre 94270, France; Institute of Integrative Biology of the Cell - UMR 9196, Paris Saclay University, Gif-sur-Yvette 91190, France
| | - Richard Lo-Man
- Neonatal Immunity Group, Human Histopathology and Animal Models, Institut Pasteur, Paris 75724, France.
| |
Collapse
|